



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07K 14/00</p>	<p>A2</p>	<p>(11) International Publication Number: WO 00/24771</p> <p>(43) International Publication Date: 4 May 2000 (04.05.00)</p>																											
<p>(21) International Application Number: PCT/US99/24913</p> <p>(22) International Filing Date: 22 October 1999 (22.10.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%;"> <tr> <td style="width: 40%;">60/105,481</td> <td style="width: 30%;">23 October 1998 (23.10.98)</td> <td style="width: 30%;">US</td> </tr> <tr> <td>60/156,993</td> <td>1 October 1999 (01.10.99)</td> <td>US</td> </tr> <tr> <td>09/422,680</td> <td>21 October 1999 (21.10.99)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table style="width: 100%;"> <tr> <td style="width: 40%;">US</td> <td style="width: 30%;">60/105,481 (CIP)</td> <td style="width: 30%;"></td> </tr> <tr> <td>Filed on</td> <td>23 October 1998 (23.10.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/156,993 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>1 October 1999 (01.10.99)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>21 October 1999 (21.10.99)</td> <td></td> </tr> </table> <p>(71) Applicant (for all designated States except US): CURAGEN CORPORATION [US/US]; 11th floor, 555 Long Wharf Drive, New Haven, CT 06511 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US).</p>		60/105,481	23 October 1998 (23.10.98)	US	60/156,993	1 October 1999 (01.10.99)	US	09/422,680	21 October 1999 (21.10.99)	US	US	60/105,481 (CIP)		Filed on	23 October 1998 (23.10.98)		US	60/156,993 (CIP)		Filed on	1 October 1999 (01.10.99)		US	Not furnished (CIP)		Filed on	21 October 1999 (21.10.99)		<p>YANG, Meijia [CN/US]; 6 Catbird Lane, East Lyme, CT 06533 (US). LICHENSTEIN, Henri [US/US]; 24 Sheep Pasture Road, Madison, CT 06443 (US). MCDONALD, William, F. [US/US]; 343 Warpas Road, Madison, CT 06443 (US).</p> <p>(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
60/105,481	23 October 1998 (23.10.98)	US																											
60/156,993	1 October 1999 (01.10.99)	US																											
09/422,680	21 October 1999 (21.10.99)	US																											
US	60/105,481 (CIP)																												
Filed on	23 October 1998 (23.10.98)																												
US	60/156,993 (CIP)																												
Filed on	1 October 1999 (01.10.99)																												
US	Not furnished (CIP)																												
Filed on	21 October 1999 (21.10.99)																												
<p>(54) Title: NUCLEIC ACIDS ENCODING OSTEOPROTEGERIN-LIKE PROTEINS AND METHODS OF USING SAME</p> <p>(57) Abstract</p> <p>Disclosed are osteoprotegerin-like polypeptides, nucleic acids encoding osteoprotegerin-like polypeptides, and methods of using these molecules. The osteoprotegerin-like polypeptides sequence homology to osteoprotegerin and tumor necrosis factor receptor molecules.</p>																													

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NUCLEIC ACIDS ENCODING OSTEOPROTEGERIN-LIKE PROTEINS AND METHODS OF USING SAME

RELATED APPLICATIONS

This patent application claims priority to the United States Nonprovisional Patent
5 Application entitled "NUCLEIC ACIDS ENCODING OSTEOPROTEGERIN-LIKE PROTEINS
AND METHODS OF USING SAME" filed October 21, 1999, and United States Provisional
Patent Applications USSN 60/105,481, filed October 23, 1998, and USSN 60/156,993, filed
October 1, 1999, which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

10 The invention relates in general to nucleic acids and proteins and in particular to nucleic
acids and their encoded polypeptides involved in metabolic bone diseases, such as osteoporosis
or osteopetrosis.

BACKGROUND OF THE INVENTION

Bone is a highly dynamic tissue characterized by continuous formation and readsorption.
15 An imbalance in formation and readsorption can be implicated in metabolic bone diseases such
as osteopetrosis and osteoporosis.

Bone formation and readsorption is mediated at least in part by osteoblasts and
osteoclasts. These cells exert opposite effects on bone growth. Osteoblasts secrete molecules
that form the organic matrix of bone, while osteoclasts promote dissolution of the bone matrix
20 and solubilization of bone salts. Net bone tissue formation occurs when the rate of bone
deposition exceeds the rate of bone resorption, while bone loss occurs when the rate of resorption
exceeds deposition. Increased breakdown of bone, as is observed in diseases such as
osteoporosis, can lead to reduced bone mass and strength, as well as an increased risk of
fractures, and slow or incomplete repair of broken bones.

25 Osteoclasts are thought to form from hematopoietic precursor cells in the bone marrow.
Early development of bone marrow precursor cells to preosteoclasts are believed to mediated by
soluble factors such as tumor necrosis factor-alpha. (TNF-alpha), tumor necrosis factor-beta
(TNF-beta), interleukin-1 (IL-1), interleukin-4 (IL-4), interleukin-6 (IL-6), and leukemia
inhibitory factor (LIF).

One protein involved in bone metabolism is osteoprotegerin (OPG), which is also known as osteoclastogenesis inhibitory factor (OCIF). OPG includes two polypeptide domains having different structural and functional properties. It has cytokine-like activities and is a member of the tumor necrosis factor (TNF) receptor superfamily. OPG has been reported to act as a soluble factor in the regulation of bone mass by negatively regulating osteoclast formation *in vitro* and *in vivo*. By inhibiting osteoclast formation, OPG is thought to promote net bone growth. Transgenic mice expressing the OPG polypeptide show increased bone density and lowered amounts of bone loss.

OPG-deficient mice also exhibit medial calcification of the aorta and renal arteries, suggesting that regulation of OPG, its signaling pathway, or its ligand(s) may play a role in the long-observed association between osteoporosis and vascular calcification.

SUMMARY OF THE INVENTION

The invention is based in part on the discovery of novel nucleic acids encoding osteoprotegerin-like (OPGx) polypeptides. The OPGx polypeptides and nucleic acids are useful, *inter alia*, for treating disorders associated with bone metabolism.

Accordingly, in one aspect the invention features an OPGx nucleic acid. In some embodiments, the OPGx nucleic acid encodes a polypeptide that is not longer than 650 amino acids. In other embodiments, the OPGx nucleic acid encodes a polypeptide that is not longer than 600, 550, 500, 450, 400, 375, 325, 300, or even 295 amino acids.

The invention also features OPGx polypeptides. In some embodiments, the OPGx polypeptide is not longer than 650 amino acids. In other embodiments, the OPGx polypeptide is not longer than 600, 550, 500, 450, 400, 375, 325, 300, or even 295 amino acids.

Also included in the invention are antibodies to OPGx polypeptides. In some embodiments, the antibodies are monoclonal antibodies.

In other aspects, the invention features pharmaceutical compositions including an OPGx nucleic acid, pharmaceutical compositions including an OPGx polypeptide, and pharmaceutical compositions including an antibody to an OPGx polypeptide.

Also included in the invention is a method of promoting bone growth by administering to a patient in need thereof an effective amount of an OPGx polypeptide, an OPGx polypeptide agonist, or an OPGx nucleic acid.

- 3 -

The invention further includes a method of inhibiting osteoclast-mediated bone resorption by administering to a subject in need thereof an effective amount of an OPGx polypeptide, an OPGx agonist, or an OPGx nucleic acid.

5 The patient can be, e.g., a human or a non-human mammal such as a dog, cat, horse, cow, sheep, or goat. The patient can suffer from, e.g., osteoporosis, osteopetrosis, or another condition characterized by loss of bone, breakdown of bone tissue, or excessive reabsorption of bone tissue.

10 The details of one or more embodiments of the invention are set forth in the accompanying description below. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same
15 meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated by reference.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE FIGURES

20 Figure 1 illustrates the nucleic acid (SEQ ID NO:1) and translated amino acid (SEQ ID NO:2) residue sequences of a human OPGx1 protein.

Figure 2 illustrates the nucleic acid (SEQ ID NO:3) and translated amino acid (SEQ ID NO:4) residue sequences of a human OPGx2 protein.

25 Figure 3 illustrates a sequence comparison of a portion of the OPGx polypeptide (Query) with a related sequence from human osteoprotegerin protein having 401 amino acid residues (Sbjct). Residue numbers shown are relative.

Figure 4 illustrates a sequence comparison of a portion of the OPGx polypeptide (Query) with a related sequence from human tissue necrosis factor (TNF) receptor having 425 amino acid residues (Sbjct). Residue numbers shown are relative.

Figure 5 illustrates the nucleic acid (SEQ ID NO:5) and translated amino acid (SEQ ID NO:6) residue sequence of a human OPGx3 protein.

Figure 6 illustrates the nucleic acid (SEQ ID NO:7) and translated amino acid (SEQ ID NO:8) residue sequences of a human OPGx4 protein.

5 Figure 7 shows Western blots of SDS PAGE experiments on the product obtained when hOPGx protein is secreted by 293 cells (Panel A), and by SF9 cells (Panel B).

Figure 8 shows SDS-PAGE and silver staining analysis of 250 ng of purified OPGx-Ig protein.

10 Figure 9 illustrates (Panel A) the nucleic acid (SEQ ID NO:9) and (Panel B) translated amino acid (SEQ ID NO:10) residue sequences of a murine OPGx5 protein.

DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are nucleic acids encoding osteoprotegerin-like polypeptide sequences (OPGx) and their polypeptide products. The nucleotide sequences of these OPGx sequences, along with their encoded polypeptides, are shown in Figures 1, 2, 5 6, and 9. Figure 1 illustrates the sequence of OPGX1, which includes a 1686 nucleic acid sequence (SEQ ID NO:1) along with an encoded polypeptide of 290 amino acids (SEQ ID NO:2).

Figure 2 illustrates the sequence of OPGX2, which includes a nucleic acid sequence of 2271 nucleotides (SEQ ID NO:3), along with an encoded polypeptide of 691 amino acids (SEQ ID NO:4).

20 The 773 nucleic acid sequence of OPGX3 (SEQ ID NO:5), along with an encoded polypeptide of 254 amino acids (SEQ ID NO:6), is shown in Figure 5. Figure 6 illustrates the sequence of OPGX4, which includes a nucleic acid sequence of 1686 nucleotides and an encoded polypeptide of 190 amino acids. Figure 9 shows the 2314 nucleotide sequence of OPGX5 (SEQ ID NO:9), along with an encoded polypeptide of 600 amino acids. The OPGX1-4 sequences shown are of human origin, while the OPGX5 sequence is of murine origin.

25 OPGX1, OPGX2, and OPGX4 contain a 36 amino acid extension (SEQ ID NO:23) at their amino terminus relative to the DR6 TNF-related death receptor amino acid sequence (Accession AF068868.1). Expression of the OPGx proteins is found in bone, lymph node, germinal B cells and kidney. In addition, there appears to be at least two splice variants of this

- 5 -

gene, a transmembrane form and a extracellular domain form (compare FIGS. 2 and 9 with FIGS. 1, 5 and 6).

The amino acid sequences of OPGX1, OPGX3, and OPGX4 (SEQ ID NOS:2, 6, and 8) terminate just before the TNF receptor family transmembranal domain. This structural motif indicates at least some OPGx proteins may be secreted. Hydropathy and signal peptide analyses also indicate that some OPGx proteins may be secreted. Structural motif computer programs have identified a TNF receptor-like structural "signature." Additionally, cysteine amino acid residue alignment within the TNF receptor and the osteoprotegerin-like protein of the present invention show the cysteines of TNF receptor and OPGx can be aligned in at least some of the OPGx proteins of the invention.

The OPGx proteins are useful, *inter alia*, in modulating bone formation, osteoporosis, anti-inflammation and in modulating cell death, e.g., inducing apoptotic pathways by administering OPGx polypeptides, OPGx nucleic acids, or OPGx agonists, or inhibiting apoptotic pathways by administering OPGx antagonists. Members of the TNF receptor and ligand super-families play an important role in the regulation of numerous biological processes including, but not limited to: cytokine production, apoptosis, cell activation, lymphocyte co-stimulation, immunoglobulin secretion and immunoglobulin isotype switching.

The OPGx proteins inhibiting osteoclast-mediated bone reabsorption in a subject that is suspected of experiencing osteoclast-mediated bone reabsorption or is at risk of developing osteoclast-mediated bone reabsorption, as well as treating a subject that is suffering from a decrease in bone mass or is at risk of undergoing a decrease in bone mass. As is discussed in detail below, the methods include administering an amount the polypeptides or polynucleotides of the invention in amounts, and for durations of time, that are effective to inhibit reabsorption in the subject, or that are effective to treat the subject. The appropriate amounts and durations to be administered, or that are used in the treatments, may be assessed or evaluated by studying subjects undergoing such administering or such treatments. Practitioners skilled in the veterinarian (in the case of nonhuman subjects) and medical (in the case of human subjects) specialties such as orthopedics, radiology, and geriatric gynecology have sufficient training to evaluate the effectiveness of such methods. Techniques employed to assess the efficacy of treatment include any procedures or diagnostic methods capable of assessing bone density and/or bone mass, for example, and include, by way of nonlimiting example, various radiological

procedures such as x-ray imaging and tomography, bone-specific radioisotope imaging, magnetic resonance imaging, and ultrasonography. A treatment may be considered effective by a variety of criteria, including but not limited to reversing an actual decrease in bone mass, achieving a steady level or extent of bone mass, and regeneration of depleted bone mass.

5 **OPGx Nucleic Acids**

One aspect of the invention pertains to isolated nucleic acid molecules that encode OPGx proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify OPGx-encoding nucleic acids (*e.g.*, OPGx mRNA) and fragments for use as PCR primers for the amplification or mutation of OPGx nucleic acid
10 molecules. The nucleic acid may encode a polypeptide which includes the amino acid sequence MetGlySerArgProGlyGlyGlyGlyGlyCysGlyAlaGlyGlnLysGlnProProlleProAlaAlaProArgAla ProAlaThrLeuArgValProGlySerAla (SEQ ID NO:23), or a polypeptide having one or more conservative amino acid substitutions within this sequence. The remainder of the nucleic acid may hybridize to one or more of the remaining regions of an OPGx nucleic acid described herein,
15 as discussed below. Alternatively, the nucleic acid may encode a polypeptide comprising SEQ ID NO:23, or with one or more conservative amino substitutions therein.

As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The
20 nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

An "isolated" nucleic acid molecule is one that is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at
25 the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated OPGx nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, 0.1 or 0.01 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a
30 cDNA molecule, can be substantially free of other cellular material or culture medium when

produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7 or 9, or a complement of any of these nucleotide sequences, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequences of SEQ ID NOs: 1, 3, 5, 7 or 9 as a hybridization probe, OPGx nucleic acid molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook *et al.*, eds., MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to OPGx nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NOs: 1, 3, 5, 7 or 9. In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in, or a portion of this nucleotide sequence. A nucleic acid molecule that is complementary to the nucleotide sequence shown in SEQ ID NOs: 1, 3, 5, 7 or 9 is one that is sufficiently complementary to the nucleotide sequence shown in SEQ ID NOs: 1, 3, 5, 7 or 9 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown in SEQ ID NOs: 1, 3, 5, 7 or 9, thereby forming a stable duplex.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NOs: 1, 3, 5, 7 or 9, *e.g.*, a fragment that can be used as a probe or primer or a fragment encoding a biologically active portion of OPGx. Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or

for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by
5 modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are
10 derived from different species.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the
15 invention, in various embodiments, by at least about 30%, 50%, 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding these proteins under stringent, moderately stringent, or
20 low stringent conditions. See *e.g.* Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

The nucleotide sequence determined from the cloning of the human OPGx gene allows for the generation of probes and primers designed for use in identifying and/or cloning OPGx homologues in other cell types, *e.g.*, from other tissues, as well as OPGx homologues from other
25 mammals. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7 or 9; or an anti-sense strand nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7 or 9; or of a naturally occurring mutant of SEQ
30 ID NOs: 1, 3, 5, 7 or 9.

Probes based on the human OPGx nucleotide sequence can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, *e.g.*, the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a OPGx protein, such as by measuring a level of a OPGx-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting OPGx mRNA levels or determining whether a genomic OPGx gene has been mutated or deleted.

"A polypeptide having a biologically active portion of OPGx" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically active portion of OPGx" can be prepared by isolating a portion of SEQ ID NOs: 1, 3, 5, 7 or 9, that encodes a polypeptide having a OPGx biological activity (the biological activities of the OPGx proteins are described below), expressing the encoded portion of OPGx protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of OPGx.

Also included in the invention are nucleic acids encoding polypeptides having one or more OPGx activities. These include, *e.g.*, (i) binding to the cytotoxic ligand TRAIL (Emery, et al., J Biol Chem. 1998):14363-7, and (ii) binding to the osteoprotegerin ligand (Lacey DL, et al., Cell. 1998 Apr 17;93(2):165-76).

OPGx variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NOs: 1, 3, 5, 7 or 9, due to degeneracy of the genetic code and thus encode the same OPGx protein as that encoded by the nucleotide sequence shown in SEQ ID NOs: 1, 3, 5, 7 or 9. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NOs. 2, 4, 6, 8 or 10.

In addition to the human OPGx nucleotide sequences shown in SEQ ID NO:1, 3, 5, or 7, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of OPGx may exist within a population (*e.g.*, the human population). Such genetic polymorphism in the OPGx gene may exist among individuals within

- 10 -

a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a OPGx protein, preferably a mammalian OPGx protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the OPGx gene. Any and all such
5 nucleotide variations and resulting amino acid polymorphisms in OPGx that are the result of natural allelic variation and that do not alter the functional activity of OPGx are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding OPGx proteins from other species, and thus that have a nucleotide sequence that differs from the sequence of SEQ ID NOs: 1, 3, 5, 7 or 9, are
10 intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the OPGx cDNAs of the invention can be isolated based on their homology to the human or murine OPGx nucleic acids disclosed herein using the human or murine sequences, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. For example, a soluble human
15 OPGx cDNA can be isolated based on its homology to human membrane-bound OPGx. Likewise, a membrane-bound human OPGx cDNA can be isolated based on its homology to soluble human OPGx.

In another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule
20 comprising the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7 or 9. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250 or 500 nucleotides in length. In another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each
25 other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding OPGx proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

30 Stringent conditions are known to those skilled in the art and can be found in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably,

the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NOs: 1, 3, 5, 7 or 9 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7 or 9, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well-known in the art. See, e.g., Ausubel *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7 or 9, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981, *Proc Natl Acad Sci USA* 78: 6789-6792.

Conservative mutations

In addition to naturally-occurring allelic variants of the OPGx sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7 or 9, thereby leading to changes in the amino acid sequence of the encoded OPGx protein, without altering the functional ability of the OPGx protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NOs: 1, 3, 5, 7 or 9. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of OPGx without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the OPGx proteins of the present invention, are predicted to be particularly unamenable to alteration.

Another aspect of the invention pertains to nucleic acid molecules encoding OPGx proteins that contain changes in amino acid residues that are not essential for activity. Such OPGx proteins differ in amino acid sequence from SEQ ID NOs: 2, 4, 6, 8 or 10, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO:2, 4, 6, 8, of 10. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NOs: 2, 4, 6, 8 or 10, more preferably at least about 70% homologous to SEQ ID NO:2, 4, 6, 8 or 10, still more preferably at least about 80% homologous to SEQ ID NO:2, 4, 6, 8 or 10, even more preferably at least about 90% homologous to SEQ ID NO:2, 4, 6, 8 or 10, and most preferably at least about 95% homologous to SEQ ID NO:2, 4, 6, 8 or 10.

An isolated nucleic acid molecule encoding a OPGx protein homologous to the protein of SEQ ID NOs:2, 4, 6, 8 or 10 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7 or 9, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into SEQ ID NOs: 1, 3, 5, 7 or 9 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an

amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in OPGx is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a OPGx coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for OPGx biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NOs: 1, 3, 5, 7 or 9, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

In one embodiment, a mutant OPGx protein can be assayed for (1) the ability to form protein:protein interactions with other OPGx proteins, other cell-surface proteins, or biologically active portions thereof, (2) complex formation between a mutant OPGx protein and a OPGx ligand; (3) the ability of a mutant OPGx protein to bind to an intracellular target protein or biologically active portion thereof; (*e.g.* avidin proteins).

In yet another embodiment, a mutant OPGx can be assayed for the ability to perform TNF receptor super family member activities, such as, (i) complex formation between a OPGx protein and an osteoprotegerin ligand protein, as described in and (ii) interaction of a OPGx protein with other proteins. In yet another embodiment, a OPGx activity is at least one or more of the following activities: (i) modulation of TNF superfamily-related protein activity; and (ii) regulation of apoptosis, *e.g.*, induction of apoptosis.

Antisense

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7 or 9, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded

cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire OPGx coding strand, or to only a portion thereof.

5 Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a OPGx protein of SEQ ID NOs: 1, 3, 5, 7 or 9, or antisense nucleic acids complementary to a OPGx nucleic acid sequence of SEQ ID NOs: 1, 3, 5, 7 or 9, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding OPGx. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid
10 residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding OPGx. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding OPGx disclosed herein (*e.g.*, SEQ ID NOs:
15 1, 3, 5, 7 or 9), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of OPGx mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of OPGx mRNA. For example, the antisense oligonucleotide can be complementary to the region
20 surrounding the translation start site of OPGx mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or
25 variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used.

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine,
30 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine,

- 15 -

inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-
5 N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the
10 antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or
15 genomic DNA encoding a OPGx protein to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the
20 invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The
25 antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an
30 α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the

strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res* 15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res* 15: 6131-6148) or a chimeric RNA -DNA analogue (Inoue *et al.* (1987) *FEBS Lett* 215: 327-330).

5 **Ribozymes and PNA moieties**

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave OPGx mRNA transcripts to thereby inhibit translation of OPGx mRNA. A ribozyme having specificity for a OPGx-encoding nucleic acid can be designed based upon the nucleotide sequence of a OPGx cDNA disclosed herein (*i.e.*, SEQ ID NOs: 1, 3, 5, 7 or 9). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the
15 nucleotide sequence to be cleaved in a OPGx-encoding mRNA. See, *e.g.*, Cech *et al.* U.S. Pat. No. 4,987,071; and Cech *et al.* U.S. Pat. No. 5,116,742. Alternatively, OPGx mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel *et al.*, (1993) *Science* 261:1411-1418.

Alternatively, OPGx gene expression can be inhibited by targeting nucleotide sequences
20 complementary to the regulatory region of the OPGx (*e.g.*, the OPGx promoter and/or enhancers) to form triple helical structures that prevent transcription of the OPGx gene in target cells. See generally, Helene. (1991) *Anticancer Drug Des.* 6: 569-84; Helene. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher (1992) *Bioassays* 14: 807-15.

In various embodiments, the nucleic acids of OPGx can be modified at the base moiety,
25 sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup *et al.* (1996) *Bioorg Med Chem* 4: 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide
30 backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic

strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup *et al.* (1996) above; Perry-O'Keefe *et al.* (1996) *PNAS* 93: 14670-675.

PNAs of OPGx can be used in therapeutic and diagnostic applications. For example, PNA
5 PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs of OPGx can also be used, *e.g.*, in the analysis of single base pair mutations in a gene by, *e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.*, S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence
10 and hybridization (Hyrup *et al.* (1996), above; Perry-O'Keefe (1996), above).

In another embodiment, PNAs of OPGx can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of OPGx can be generated that may combine the
15 advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, *e.g.*, RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can
20 be performed as described in Hyrup (1996) above and Finn *et al.* (1996) *Nucl Acids Res* 24: 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag *et al.* (1989) *Nucl Acid Res* 17: 5973-88). PNA monomers are then
25 coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn *et al.* (1996) above). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, Petersen *et al.* (1975) *Bioorg Med Chem Lett* 5: 1119-1124.

In other embodiments, the oligonucleotide may include other appended groups such as
30 peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556;

Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci.* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, *e.g.*, Krol *et al.*, 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, *e.g.*, Zon, 1988, *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, etc.

OPGx proteins

One aspect of the invention pertains to isolated OPGx proteins, and biologically active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-OPGx antibodies. In one embodiment, native OPGx proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, OPGx proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a OPGx protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the OPGx protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of OPGx protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of OPGx protein having less than about 30% (by dry weight) of non-OPGx protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-OPGx protein, still more preferably less than about 10% of non-OPGx protein, and most preferably less than about 5% non-OPGx protein. When the OPGx protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of OPGx protein in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of OPGx protein having less than about 30% (by dry weight) of chemical precursors or non-OPGx chemicals, more preferably less than about 20% chemical precursors or non-OPGx chemicals, still more preferably less than about 10% chemical precursors or non-OPGx chemicals, and most preferably less than about 5% chemical precursors or non-OPGx chemicals.

Biologically active portions of a OPGx protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the OPGx protein, *e.g.*, the amino acid sequence shown in SEQ ID NOs: 2, 4, 6, 8 or 10, that include fewer amino acids than the full length OPGx proteins, and exhibit at least one activity of a OPGx protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the OPGx protein. A biologically active portion of a OPGx protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.

Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native OPGx protein.

In some embodiments, the OPGx protein has an amino acid sequence shown in SEQ ID NOs: 2, 4, 6, 8 or 10. In other embodiments, the OPGx protein is substantially homologous to SEQ ID NOs: 2, 4, 6, 8 or 10 and retains the functional activity of the protein of SEQ ID NOs: 2, 4, 6, 8 or 10, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail below. Accordingly, in another embodiment, the OPGx protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO: 2, 4, 6, 8 or 10 and retains the functional activity of the OPGx proteins having these amino acid sequences.

Determining homology between two or more sequences

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino

acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

5 The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch 1970 *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of
10 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOs: 1, 3, 5, 7 or 9.

 The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of
15 comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window
20 size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison
25 region.

Chimeric and fusion proteins

 The invention also provides OPGx chimeric or fusion proteins. As used herein, a OPGx "chimeric protein" or "fusion protein" comprises a OPGx polypeptide operatively linked to a non-OPGx polypeptide. A "OPGx polypeptide" refers to a polypeptide having an amino acid
30 sequence corresponding to OPGx, whereas a "non-OPGx polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to

the OPGx protein, *e.g.*, a protein that is different from the OPGx protein and that is derived from the same or a different organism. Within a OPGx fusion protein the OPGx polypeptide can correspond to all or a portion of a OPGx protein. In one embodiment, a OPGx fusion protein comprises at least one biologically active portion of a OPGx protein. In another embodiment, a OPGx fusion protein comprises at least two biologically active portions of a OPGx protein. In yet another embodiment, a OPGx fusion protein comprises at least three biologically active portions of a OPGx protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the OPGx polypeptide and the non-OPGx polypeptide are fused in-frame to each other. The non-OPGx polypeptide can be fused to the N-terminus or C-terminus of the OPGx polypeptide.

For example, in one embodiment a OPGx fusion protein comprises a OPGx domain operably linked to the extracellular domain of a second protein. Such fusion proteins can be further utilized in screening assays for compounds which modulate OPGx activity (such assays are described in detail below).

In yet another embodiment, the fusion protein is a GST-OPGx fusion protein in which the OPGx sequences are fused to the C-terminus of the GST (*i.e.*, glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant OPGx.

In another embodiment, the fusion protein is a OPGx protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of OPGx can be increased through use of a heterologous signal sequence.

A OPGx chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, *e.g.*, by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY,

John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). A OPGx-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the OPGx protein.

5 **Anti-OPGx antibodies**

 An isolated OPGx protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind OPGx using standard techniques for polyclonal and monoclonal antibody preparation. The full-length OPGx protein can be used or, alternatively, the invention provides antigenic peptide fragments of OPGx for use as immunogens. The
10 antigenic peptide of OPGx comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NOs: 2, 4, 6, 8 or 10 and encompasses an epitope of OPGx such that an antibody raised against the peptide forms a specific immune complex with OPGx. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at
15 least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of OPGx that are located on the surface of the protein, *e.g.*, hydrophilic regions.

 As disclosed herein, OPGx protein sequence of SEQ ID NOs: 2, 4, 6, 8 or 10, or derivatives, fragments, analogs or homologs thereof, may be utilized as immunogens in the generation of antibodies that immunospecifically-bind these protein components. The term
20 "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen, such as OPGx. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab} and F_{(ab)₂} fragments, and an F_{ab} expression library. In a specific embodiment, antibodies to human OPGx proteins are
25 disclosed. Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies to a OPGx protein sequence of SEQ ID NOs: 2, 4, 6, 8 or 10, or derivatives, fragments, analogs or homologs thereof.

 For the production of polyclonal antibodies, various suitable host animals (*e.g.*, rabbit, goat, mouse or other mammal) may be immunized by injection with the native protein, or a
30 synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic

preparation can contain, for example, recombinantly expressed OPGx protein or a chemically synthesized OPGx polypeptide. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (*e.g.*, aluminum hydroxide), surface active substances (*e.g.*, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), human adjuvants such as *Bacille Calmette-Guerin* and *Corynebacterium parvum*, or similar immunostimulatory agents. If desired, the antibody molecules directed against OPGx can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction.

10 The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of OPGx. A monoclonal antibody composition thus typically displays a single binding affinity for a particular OPGx protein with which it immunoreacts. For preparation of monoclonal antibodies directed towards a particular
15 OPGx protein, or derivatives, fragments, analogs or homologs thereof, any technique that provides for the production of antibody molecules by continuous cell line culture may be utilized. Such techniques include, but are not limited to, the hybridoma technique (see Kohler & Milstein, 1975 *Nature* 256: 495-497); the trioma technique; the human B-cell hybridoma technique (see Kozbor, *et al.*, 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to
20 produce human monoclonal antibodies (see Cole, *et al.*, 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, *et al.*, 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus *in vitro* (see Cole, *et al.*, 1985 In: MONOCLONAL ANTIBODIES AND
25 CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to a OPGx protein (see *e.g.*, U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see *e.g.*, Huse, *et al.*, 1989 *Science* 246: 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the
30 desired specificity for a OPGx protein or derivatives, fragments, analogs or homologs thereof. Non-human antibodies can be "humanized" by techniques well known in the art. See *e.g.*, U.S.

Patent No. 5,225,539. Antibody fragments that contain the idiotypes to a OPGx protein may be produced by techniques known in the art including, but not limited to: (i) an $F_{(ab')_2}$ fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an $F_{(ab')_2}$ fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

Additionally, recombinant anti-OPGx antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT International Application No. PCT/US86/02269; European Patent Application No. 184,187; European Patent Application No. 171,496; European Patent Application No. 173,494; PCT International Publication No. WO 86/01533; U.S. Pat. No. 4,816,567; European Patent Application No. 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *PNAS* 84:3439-3443; Liu *et al.* (1987) *J Immunol.* 139:3521-3526; Sun *et al.* (1987) *PNAS* 84:214-218; Nishimura *et al.* (1987) *Cancer Res* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; Shaw *et al.* (1988) *J Natl Cancer Inst* 80:1553-1559; Morrison (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214; U.S. Pat. No. 5,225,539; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeyan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J Immunol* 141:4053-4060.

In one embodiment, methodologies for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of a OPGx protein is facilitated by generation of hybridomas that bind to the fragment of a OPGx protein possessing such a domain. Antibodies that are specific for a domain within a OPGx protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

Anti-OPGx antibodies may be used in methods known within the art relating to the localization and/or quantitation of a OPGx protein (*e.g.*, for use in measuring levels of the OPGx protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies for OPGx proteins, or

derivatives, fragments, analogs or homologs thereof, that contain the antibody derived binding domain, are utilized as pharmacologically-active compounds [hereinafter "Therapeutics"].

An anti-OPGx antibody (*e.g.*, monoclonal antibody) can be used to isolate OPGx by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-OPGx antibody can facilitate the purification of natural OPGx from cells and of recombinantly produced OPGx expressed in host cells. Moreover, an anti-OPGx antibody can be used to detect OPGx protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the OPGx protein. Anti-OPGx antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

OPGx Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding OPGx protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are

replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be
5 used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the
10 invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that
15 allows for expression of the nucleotide sequence. This can include, *e.g.*, an *in vitro* transcription/translation system or a host cell when the vector is introduced into the host cell. The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; GENE EXPRESSION TECHNOLOGY: METHODS IN
20 ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be
25 transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, OPGx proteins, mutant forms of OPGx, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of
30 OPGx in prokaryotic or eukaryotic cells. For example, OPGx can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian

cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase."

5 Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (1) to increase expression of recombinant protein; (2) to increase the solubility of
10 the recombinant protein; and (3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin
15 and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

 Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc
20 (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

 One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant
25 protein. See, Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out
30 by standard DNA synthesis techniques.

In another embodiment, the OPGx expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, (1987) *EMBO J* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

Alternatively, OPGx can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, SF9 cells) include the pAc series (Smith *et al.* (1983) *Mol Cell Biol* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J* 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells. See, *e.g.*, Chapters 16 and 17 of Sambrook *et al.*, *MOLECULAR CLONING: A LABORATORY MANUAL*. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv Immunol* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle (1989) *PNAS* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also

encompassed, *e.g.*, the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to OPGx mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub *et al.*, "Antisense RNA as a molecular tool for genetic analysis," Reviews--Trends in Genetics, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, OPGx protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium

chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory
5 manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host
10 cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding OPGx or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene
15 will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) OPGx protein. Accordingly, the invention further provides methods for producing OPGx protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression
20 vector encoding OPGx has been introduced) in a suitable medium such that OPGx protein is produced. In another embodiment, the method further comprises isolating OPGx from the medium or the host cell.

Transgenic animals

The host cells of the invention can also be used to produce nonhuman transgenic animals.
25 For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which OPGx-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous OPGx sequences have been introduced into their genome or homologous recombinant animals in which
endogenous OPGx sequences have been altered. Such animals are useful for studying the
30 function and/or activity of OPGx and for identifying and/or evaluating modulators of OPGx activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal,

more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous OPGx gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing OPGx-encoding nucleic acid into the male pronuclei of a fertilized oocyte, *e.g.*, by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The human OPGx DNA sequence of SEQ ID NOs: 2, 4, 6, or 8 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of the human OPGx gene, such as a mouse OPGx gene, can be isolated based on hybridization to the human OPGx cDNA (described further above) and used as a transgene. Intron sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the OPGx transgene to direct expression of OPGx protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan 1986, In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the OPGx transgene in its genome and/or expression of OPGx mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding OPGx can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a OPGx gene into which a deletion, addition or substitution has been introduced to

thereby alter, *e.g.*, functionally disrupt, the OPGx gene. The OPGx gene can be a human gene (*e.g.*, the DNA of SEQ ID NOs: 2, 4, 6, or 8, but more preferably, is a non-human homologue of a human OPGx gene. For example, a mouse homologue of a human OPGx gene, *e.g.*, SEQ ID NO:10, can be used to construct a homologous recombination vector suitable for altering an
5 endogenous OPGx gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous OPGx gene is functionally disrupted (*i.e.*, no longer encodes a functional protein: also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous OPGx gene is mutated or otherwise altered but still encodes functional protein (*e.g.*,
10 the upstream regulatory region can be altered to thereby alter the expression of the endogenous OPGx protein). In the homologous recombination vector, the altered portion of the OPGx gene is flanked at its 5' and 3' ends by additional nucleic acid of the OPGx gene to allow for homologous recombination to occur between the exogenous OPGx gene carried by the vector and an endogenous OPGx gene in an embryonic stem cell. The additional flanking OPGx
15 nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector. See *e.g.*, Thomas *et al.* (1987) *Cell* 51:503 for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced OPGx gene has homologously
20 recombined with the endogenous OPGx gene are selected (see *e.g.*, Li *et al.* (1992) *Cell* 69:915).

The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras. See *e.g.*, Bradley 1987, In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH. Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo
25 brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Curr Opin Biotechnol* 2:823-829; PCT International Publication Nos.: WO 90/11354;
30 WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, *e.g.*, Lakso *et al.* (1992) *PNAS* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.* (1991) *Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g.*, by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut *et al.* (1997) *Nature* 385:810-813. In brief, a cell, *e.g.*, a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, *e.g.*, through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, *e.g.*, the somatic cell, is isolated.

20 **Pharmaceutical Compositions**

The OPGx nucleic acid molecules, OPGx proteins, and anti-OPGx antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, 5 intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for 10 the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of 15 sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of 20 microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the 25 action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays 30 absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, a OPGx protein or anti-OPGx antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or

suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

5 In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will
10 be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

15 It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for
20 the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

 The nucleic acid molecules of the invention can be inserted into vectors and used as gene
25 therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, injection, *e.g.* (see U.S. Patent Nos. 5,589,466, and 5,580,859), intravenous injection, *e.g.*, local administration (see U.S. Pat. No. 5,328,470) or by stereotactic injection (see *e.g.*, Chen *et al.* (1994) *PNAS* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in
30 which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery

vector can be produced intact from recombinant cells. *e.g.*, retroviral vectors. the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

5 The isolated nucleic acid molecules of the invention can be used to express OPGx protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect OPGx mRNA (*e.g.*, in a biological sample) or a genetic lesion in a OPGx gene, and to modulate OPGx activity, as described further below. In addition, the OPGx proteins can be used to screen
10 drugs or compounds that modulate the OPGx activity or expression as well as to treat disorders characterized by insufficient or excessive production of OPGx protein or production of OPGx protein forms that have decreased or aberrant activity compared to OPGx wild type protein (*e.g.* proliferative disorders such as cancer or preclampsia. In addition, the anti-OPGx antibodies of the invention can be used to detect and isolate OPGx proteins and modulate OPGx activity.

15 This invention further pertains to novel agents identified by the above described screening assays and uses thereof for treatments as described herein.

Screening Assays

20 The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) that bind to OPGx proteins or have a stimulatory or inhibitory effect on, for example, OPGx expression or OPGx activity.

25 In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a OPGx protein or polypeptide or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library
30 methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule
libraries of compounds (Lam (1997) *Anticancer Drug Des* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc Natl Acad Sci U.S.A.* 90:6909; Erb *et al.* (1994) *Proc Natl Acad Sci U.S.A.* 91:11422; Zuckermann *et al.* (1994) *J Med Chem* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew Chem Int Ed Engl* 33:2059; Carell *et al.* (1994) *Angew Chem Int Ed Engl* 33:2061; and Gallop *et al.* (1994) *J Med Chem* 37:1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), on chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner U.S. Pat. No. 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla *et al.* (1990) *Proc Natl Acad Sci U.S.A.* 87:6378-6382; Felici (1991) *J Mol Biol* 222:301-310; Ladner above.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of OPGx protein, or a biologically active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a OPGx protein determined. The cell, for example, can be of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the OPGx protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the OPGx protein or biologically active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of OPGx protein, or a biologically active portion thereof, on the cell surface with a known compound which binds OPGx to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a OPGx protein, wherein determining the ability of the test compound to interact with a OPGx protein comprises determining the ability of the test compound to preferentially bind to OPGx or a biologically active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of OPGx protein, or a biologically active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the OPGx protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of OPGx or a biologically active portion thereof can be accomplished, for example, by determining the ability of the OPGx protein to bind to or interact with a OPGx target molecule. As used herein, a "target molecule" is a molecule with which a OPGx protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a OPGx protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A OPGx target molecule can be a non-OPGx molecule or a OPGx protein or polypeptide of the present invention. In one embodiment, a OPGx target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.* a signal generated by binding of a compound to a membrane-bound OPGx molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with OPGx.

Determining the ability of the OPGx protein to bind to or interact with a OPGx target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the OPGx protein to bind to or interact with a OPGx target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular Ca^{2+} , diacylglycerol, IP_3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a OPGx-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the present invention is a cell-free assay comprising contacting a OPGx protein or biologically active portion thereof with a test compound and determining the ability of the test compound to bind to the OPGx protein or biologically active portion thereof. Binding of the test compound to the OPGx protein can be

determined either directly or indirectly as described above. In one embodiment, the assay comprises contacting the OPGx protein or biologically active portion thereof with a known compound which binds OPGx to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a OPGx protein, wherein determining the ability of the test compound to interact with a OPGx protein comprises determining the ability of the test compound to preferentially bind to OPGx or biologically active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-free assay comprising contacting OPGx protein or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the OPGx protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of OPGx can be accomplished, for example, by determining the ability of the OPGx protein to bind to a OPGx target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of OPGx can be accomplished by determining the ability of the OPGx protein further modulate a OPGx target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as previously described.

In yet another embodiment, the cell-free assay includes contacting the OPGx protein or biologically active portion thereof with a known compound which binds OPGx to form an assay mixture. The assay mixture is then contacted with a test compound, and the ability of the test compound to interact with a OPGx protein is determined. Determining the ability of the test compound to interact with a OPGx protein includes determining the ability of the OPGx protein to preferentially bind to or modulate the activity of a OPGx target molecule.

The cell-free assays of the present invention are amenable to use of both soluble forms and membrane-bound forms of OPGx. In the case of cell-free assays comprising the membrane-bound form of OPGx, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of OPGx is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, 3-(3-cholamidopropyl)dimethylamminiol-

1-propane sulfonate (CHAPS), 3-(3-cholamidopropyl)dimethylammonio-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either OPGx or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to OPGx, or interaction of OPGx with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-OPGx fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or OPGx protein, and the mixture is incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of OPGx binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either OPGx or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated OPGx or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with OPGx or target molecules, but which do not interfere with binding of the OPGx protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or OPGx trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the OPGx or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the OPGx or target molecule.

In another embodiment, modulators of OPGx expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of OPGx mRNA or protein in the cell is determined. The level of expression of OPGx mRNA or protein in the presence of the candidate compound is compared to the level of expression of OPGx mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of OPGx expression based on this comparison. For example, when expression of OPGx mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of OPGx mRNA or protein expression. Alternatively, when expression of OPGx mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of OPGx mRNA or protein expression. The level of OPGx mRNA or protein expression in the cells can be determined by methods described herein for detecting OPGx mRNA or protein.

In yet another aspect of the invention, the OPGx proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (see, *e.g.*, U.S. Pat. No. 5,283,317; Zervos *et al.* (1993) Cell 72:223-232; Madura *et al.* (1993) J Biol Chem 268:12046-12054; Bartel *et al.* (1993) Biotechniques 14:920-924; Iwabuchi *et al.* (1993) Oncogene 8:1693-1696; and Brent WO94/10300), to identify other proteins that bind to or interact with OPGx ("OPGx-binding proteins" or "OPGx-bp") and modulate OPGx activity. Such OPGx-binding proteins are also likely to be involved in the propagation of signals by the OPGx proteins as, for example, upstream or downstream elements of the OPGx pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for OPGx is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a OPGx-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription

factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with OPGx.

5 The invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

Chromosome Mapping

15 Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the OPGx sequences, described herein, can be used to map the location of the OPGx genes, respectively, on a chromosome. The mapping of the OPGx sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

20 Briefly, OPGx genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the OPGx sequences. Computer analysis of the OPGx sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the OPGx sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (*e.g.*, human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media

in which mouse cells cannot grow, because they lack a particular enzyme. but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio *et al.* (1983) *Science* 220:919-924). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the OPGx sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma *et al.*, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example, Egeland *et al.* (1987) *Nature*, 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the OPGx gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

Diagnostic Assays

An exemplary method for detecting the presence or absence of OPGx in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting OPGx protein or nucleic acid (*e.g.*, mRNA, genomic DNA) that encodes OPGx protein such that the presence of OPGx is detected in the biological sample. An agent for detecting OPGx mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to OPGx mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length OPGx nucleic acid, such as the nucleic acid of SEQ ID NOs: 1, 3, 5, 7, 9, or portions thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to OPGx mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

An agent for detecting OPGx protein is an antibody capable of binding to OPGx protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')₂) can be used. The

term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody
5 using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect OPGx mRNA, protein, or genomic DNA in a biological sample *in vitro* as
10 well as *in vivo*. For example, *in vitro* techniques for detection of OPGx mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of OPGx protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of OPGx genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of OPGx protein include
15 introducing into a subject a labeled anti-OPGx antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject
20 or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting OPGx protein, mRNA, or genomic DNA, such that the presence of OPGx protein,
25 mRNA or genomic DNA is detected in the biological sample, and comparing the presence of OPGx protein, mRNA or genomic DNA in the control sample with the presence of OPGx protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of OPGx in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting
30 OPGx protein or mRNA in a biological sample; means for determining the amount of OPGx in the sample; and means for comparing the amount of OPGx in the sample with a standard. The

compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect OPGx protein or nucleic acid.

Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects
5 having or at risk of developing a disease or disorder associated with aberrant OPGx expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with OPGx protein, nucleic acid expression or activity such as bone-metabolism associated disorders, e.g., osteoporosis, disorders characterized by unwanted cell proliferation, or
10 disorders caused by unwanted vascular calcification. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the present invention provides a method for identifying a disease or disorder associated with aberrant OPGx expression or activity in which a test sample is obtained from a subject and OPGx protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of OPGx protein
15 or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant OPGx expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a
20 subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant OPGx expression or activity. Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant OPGx expression or activity in which a test sample is obtained and
25 OPGx protein or nucleic acid is detected (e.g., wherein the presence of OPGx protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant OPGx expression or activity.)

The methods of the invention can also be used to detect genetic lesions in a OPGx gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by
30 aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion

characterized by at least one of an alteration affecting the integrity of a gene encoding a OPGx-protein, or the mis-expression of the OPGx gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of (1) a deletion of one or more nucleotides from a OPGx gene; (2) an addition of one or more nucleotides to a OPGx gene; (3) a substitution of one or more nucleotides of a OPGx gene, (4) a chromosomal rearrangement of a OPGx gene; (5) an alteration in the level of a messenger RNA transcript of a OPGx gene, (6) aberrant modification of a OPGx gene, such as of the methylation pattern of the genomic DNA, (7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a OPGx gene, (8) a non-wild type level of a OPGx-protein, (9) allelic loss of a OPGx gene, and (10) inappropriate post-translational modification of a OPGx-protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a OPGx gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, *e.g.*, U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, *e.g.*, Landegran *et al.* (1988) *Science* 241:1077-1080; and Nakazawa *et al.* (1994) *PNAS* 91:360-364), the latter of which can be particularly useful for detecting point mutations in the OPGX-gene (see Abravaya *et al.* (1995) *Nucl Acids Res* 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a OPGx gene under conditions such that hybridization and amplification of the OPGx gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (Guatelli *et al.*, 1990, *Proc Natl Acad Sci USA* 87:1874-1878), transcriptional amplification system (Kwoh, *et al.*, 1989, *Proc Natl Acad Sci USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.*,

1988, *BioTechnology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

5 In an alternative embodiment, mutations in a OPGx gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the
10 sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in OPGx can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high density arrays containing hundreds
15 or thousands of oligonucleotides probes (Cronin *et al.* (1996) *Human Mutation* 7: 244-255; Kozal *et al.* (1996) *Nature Medicine* 2: 753-759). For example, genetic mutations in OPGx can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin *et al.* above. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences
20 by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

25 In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the OPGx gene and detect mutations by comparing the sequence of the sample OPGx with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert (1977) *PNAS* 74:560 or Sanger (1977) *PNAS* 74:5463. It is also contemplated that any of a variety of
30 automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve *et al.*, (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, *e.g.*, PCT

International Publ. No. WO 94/16101; Cohen *et al.* (1996) *Adv Chromatogr* 36:127-162; and Griffin *et al.* (1993) *Appl Biochem Biotechnol* 38:147-159).

Other methods for detecting mutations in the OPGx gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers *et al.* (1985) *Science* 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type OPGx sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton *et al* (1988) *Proc Natl Acad Sci USA* 85:4397; Saleeba *et al* (1992) *Methods Enzymol* 217:286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in OPGx cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu *et al.* (1994) *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on a OPGx sequence, *e.g.*, a wild-type OPGx sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S. Pat. No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in OPGx genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita *et al.* (1989) *Proc Natl Acad Sci USA*: 86:2766. see also Cotton (1993) *Mutat Res*

285:125-144; Hayashi (1992) *Genet Anal Tech Appl* 9:73-79). Single-stranded DNA fragments of sample and control OPGx nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet* 7:5).

10 In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers *et al.* (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR.

15 In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension.

20 For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc Natl Acad Sci USA* 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the

25 hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs *et al.* (1989) *Nucleic Acids Res* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions,

30 mismatch can prevent, or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In

addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini *et al* (1992) *Mol Cell Probes* 6:1). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) *Proc Natl Acad Sci USA* 88:189). In such cases, ligation will occur
5 only if there is a perfect match at the 3' end of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein,
10 which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a OPGx gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which OPGx is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal
15 mucosal cells.

Pharmacogenomics

Agents, or modulators that have a stimulatory or inhibitory effect on OPGx activity (*e.g.*, OPGx gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (*e.g.*, cancer or gestational
20 disorders associated with aberrant OPGx activity. In conjunction with such treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug.
25 Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of OPGx protein, expression of OPGx nucleic acid, or mutation content of OPGx genes in an individual can be determined to thereby select
30 appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See *e.g.*, Eichelbaum, *Clin Exp Pharmacol Physiol*, 1996, 23:983-985 and Linder, *Clin Chem*, 1997, 43:254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

The activity of OPGx protein, expression of OPGx nucleic acid, or mutation content of OPGx genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a OPGx modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of OPGx (*e.g.*, the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase OPGx gene expression, protein levels, or upregulate OPGx activity, can be monitored in clinical trails of subjects exhibiting decreased OPGx gene expression, protein levels, or downregulated OPGx activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease OPGx gene expression, protein levels, or downregulate OPGx activity, can be monitored in clinical trails of subjects exhibiting increased OPGx gene expression, protein levels, or upregulated OPGx activity. In such clinical trials, the expression or activity of OPGx and,

preferably, other genes that have been implicated in, for example, a cellular proliferation disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

For example, and not by way of limitation, genes, including OPGX, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) that modulates OPGx activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of OPGx and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of OPGx or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a OPGx protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the OPGx protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the OPGx protein, mRNA, or genomic DNA in the pre-administration sample with the OPGx protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of OPGx to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of OPGx to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

Methods of Treatment

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant OPGx expression or activity.

5 Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be
10 utilized include, but are not limited to, (i) an OPGx polypeptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an OPGx polypeptide; (iii) nucleic acids encoding an OPGx polypeptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an OPGx polypeptide) are utilized to "knockout" endogenous function of an
15 OPGx polypeptide by homologous recombination (see, *e.g.*, Capecchi, 1989. *Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an OPGx polypeptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not
20 suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an OPGx polypeptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

25 Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an OPGx polypeptide). Methods that are well-known within the art include, but are not limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium dodecyl
30 sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or

hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ* hybridization, etc.).

Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant OPGx expression or activity, by administering to the subject an agent that modulates OPGx expression or at least one OPGx activity. Subjects at risk for a disease that is caused or contributed to by aberrant OPGx expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the OPGx aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of OPGx aberrancy, for example, a OPGx agonist or OPGx antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the present invention are further discussed in the following subsections.

Therapeutic Methods

Another aspect of the invention pertains to methods of modulating OPGx expression or activity for therapeutic purposes. As used herein, "a subject suffering from a decrease in bone mass or at risk of undergoing a decrease in bone mass" relates to a subject in which, or in whom, deposition of insoluble calcium salts in bone occurs to an extent insufficient to compensate for the processes of bone remodeling. Bone remodeling includes processes of removal of insoluble calcium salts from bone, and/or the cells involved in forming such insoluble deposits, such as osteoblasts. The subjects in question may develop this pathological condition by a number of mechanisms, including but not limited to, an insufficiency in production of an osteoclastogenesis inhibiting factor such as an osteoprotegerin. Such a subject may experience an osteoclast-mediated bone reabsorption, wherein the subject is suspected of experiencing osteoclast-mediated bone reabsorption or may be at risk of developing osteoclast-mediated bone reabsorption,

The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of OPGx protein activity associated with the cell. An agent that modulates OPGx protein activity can be an agent as described herein, such as a nucleic

acid or a protein, a naturally-occurring cognate ligand of a OPGx protein, a peptide, a OPGx peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more OPGx protein activity. Examples of such stimulatory agents include active OPGx protein and a nucleic acid molecule encoding OPGx that has been introduced into the cell. In another
5 embodiment, the agent inhibits one or more OPGx protein activity. Examples of such inhibitory agents include antisense OPGx nucleic acid molecules and anti-OPGx antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder
10 characterized by aberrant expression or activity of a OPGx protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) OPGx expression or activity. In another embodiment, the method involves administering a OPGx protein or nucleic acid molecule as therapy to compensate for reduced or
15 aberrant OPGx expression or activity.

Stimulation of OPGx activity is desirable in situations in which OPGx is abnormally downregulated and/or in which increased OPGx activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer).

20 The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

This invention is further illustrated by the following examples, which should not be
25 construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

EXAMPLES

Example 1. Expression of OPGx Proteins

30 **Cloning of OPGx cDNA for mammalian and insect cell expression.** PCR primers to amplify coding region for a human hOPGx were designed. The forward primer was 5'-act gga

- 58 -

tc CCC GGT TCA GCC ATG GGG (SEQ ID NO:11), and the reverse primer was 5'-gtc ctc gag TGA GGT TAA GT TAC CTT T GGG (SEQ ID NO:12). PCR was initiated by heating 25 ul Mix 1 (75 pmoles primers, 4 ug adult bone marrow cDNA, 5 umoles dNTPs) and 25 ul Mix 2 [1 unit Fidelity Expand polymerase (Boehringer Mannheim), 5 ul 10X Fidelity Expand Buffer] separately at 96°C for 20 seconds. Mixes 1 and 2 were then pooled, and the following PCR cycling parameters were used: 96°C, 3 min (1 cycle); 96°C, 30 sec, 55°C, 1 min, 68°C, 2 min (10 cycles); 96°C, 30 sec, 60°C, 1 min, 68°C, 2 min (20 cycles); 72°C, 7 min (1 cycle). After PCR, a single DNA fragment of approximately 0.8 kb was obtained. The DNA fragment was digested with BglII and XhoI restriction enzymes, and cloned into the pcDNA3.1 V5His vector (Invitrogen, Carlsbad, CA) or into the pBigHis vector (CuraGen Corporation). The OPGx insert was verified by DNA sequence analysis. The resulting expression vectors are called pcDNA3.1V5HisOPGx for mammalian kidney 293 cell expression and pBigHisOPGx for insect cell expression.

Expression of hOPGx in human embryonic kidney 293 cells. The pcDNA3.1V5HisOPGx vector was transfected into 293 cells using the LipofectaminePlus reagent following the manufacturer's instructions (Gibco/BRL). The cell pellet and supernatant were harvested 72 hours after transfection and examined for hOPGx expression by Western blotting (reducing conditions) with an anti-V5 antibody. Fig. 7A shows that hOPGx is expressed as a 50-kDa protein secreted by 293 cells.

Construction of pBigHis baculo expression vector. To construct the pBigHis expression vector, oligonucleotide primers were designed to amplify the Fc fragment of the human immunoglobulin heavy chain. The forward primer was 5'-CCG CTC GAG TGA GCC CAA ATC TTG TGA CAA A (SEQ ID NO:13) and the reverse primer was 5'-GCT CTA GAC TTT TAC CCG GGG ACA GGG AG (SEQ ID NO:14). PCR was initiated by heating 25 ul Mix 1 (75 pmoles primers, 4 ug adult testis cDNA, 5 umoles dNTPs) and 25 ul Mix 2 [1 unit Fidelity Expand polymerase (Boehringer Mannheim), 5 ul 10X Fidelity Expand Buffer] separately at 96°C for 20 seconds. Mixes 1 and 2 were then pooled, and the following PCR cycling parameters were used: 96°C, 3 min (1 cycle); 96°C, 30 sec, 55°C, 1 min, 68°C, 2 min (10 cycles); 96°C, 30 sec, 60°C, 1 min, 68°C, 2 min (20 cycles); 72°C, 7 min (1 cycle). After PCR, a single DNA fragment of approximately 0.75 kb was obtained. The DNA fragment was digested with XhoI and XbaI restriction enzymes and cloned into the pcDNA3.1V5His(B) expression vector

(Invitrogen, Carlsbad, CA). This vector is named as pCDNA3.1 Ig and contains Fc fragment fused to V5 epitope and 6xHis tag. At the next step a recombinant TEV protease cleavage site was introduced to the N-terminus of the Fc fragment. First, we designed two oligonucleotides 5'-AAT TCT GCA GCG AAA ACC TGT ATT TTC AGG GT (SEQ ID NO:15) and 5'-TCG AAC CCT GAA AAT ACA GGT TTT CGC TGC AG (SEQ ID NO:16). These two oligonucleotides were annealed and purified using 20% polyacrylamide gel and ligated into EcoRI and XhoI digested pCNA3.1 Ig. The resulting plasmid is then cut with PstI and PmeI to release a DNA fragment of approximately 0.9 kb, which is ligated into PstI and SmaI digested pBlueBac4.5 (Invitrogen, Carlsbad, CA). The plasmid construct obtained is named as pBIgHis. The Fc fragment was verified by sequence analysis.

Construction and isolation of recombinant baculovirus expressing hOPGx.

pBIgHisOPGx plasmid DNA was co-transfected with linearized baculovirus DNA (Bac-N-Blue) into SF9 insect cells using liposome-mediated transfer as described by the manufacturer (Invitrogen). Briefly, transfection mixtures containing 4 ug of pBIgHisOPGx, 0.5 ug of Bac-N-Blue™ and InsectinPlus™ liposomes were added to 60 mm culture dishes seeded with 2 x 10⁶ SF9 cells, and incubated with rocking at 27°C for 4 hours. Fresh culture medium was added and cultures were further incubated for 4 days. The culture medium was then harvested and recombinant viruses were isolated using standard plaque purification procedures. Recombinant viruses expressing β -galactosidase as a marker were readily distinguished from non-recombinant viruses by visually inspecting agarose overlays for blue plaques. Viral stocks were generated by propagation on SF9 cells and screened for expression of hOPGx protein by SDS-PAGE and Western blot analyses (reducing conditions, anti-V5 antibody). Fig. 7B shows that hOPGx is secreted as a 61-kDa protein.

Affinity Purification of hOPGX-Fc Chimera (hOPGX/Ig). Suspension cultures of SF9 cells grown in Grace's media containing 5% low IgG fetal calf serum were infected with recombinant hOPGX/Ig/baculovirus at a multiplicity of infection (MOI) of 0.1. Infected cultures were incubated at 27°C for 4-5 days and the conditioned medium was harvested by low-speed centrifugation to remove cells and debris. The conditioned medium was filtered through a 0.2 micron low-protein binding membrane and analyzed for hOPGx production by western analysis. The clarified conditioned medium was then loaded directly onto a 1ml protein A column (HiTap rProtein A, Amersham Pharmacia) at a flow rate of 1ml/min at room temperature. Using the

Akta Explorer™ FPLC (Amersham Pharmacia), unbound proteins were then washed from the column with 10ml of 20 mM NaPO₄ (pH 7.0). Bound hOPGX/Ig was eluted from the column with 25 mM Citrate (pH 2.8) and rapidly neutralized by collecting 0.5ml fractions in tubes containing 0.5M Hepes (pH 9.1). Fractions containing hOPGX/Ig were pooled and dialyzed
5 against phosphate buffered saline (PBS) containing 20% glycerol. Purified protein samples were stored at -20C. Using this single-step purification procedure we typically recover 3mg of hOPGX/Ig protein per liter of conditioned medium with a purity of >95%. Fig. 8 shows SDS-PAGE and silver staining analysis of 250 ng purified OPGx-Ig protein.

Example 2. Mapping of Human OPG-X

10 Oligonucleotide Design and Synthesis

Primer pairs for PCR amplification of OPG-X were designed using the Primer 3 primer selection software package. Oligonucleotides were synthesized by Integrated DNA Technologies, (Coralville, IA).

PCR, Electrophoresis and Imaging Conditions

15 PCR was carried out using the GeneBridge 4 human radiation hybrid panel (Research Genetics Inc., Huntsville, AL) as template. In addition to the 93 hybrids in the mapping panel, hamster and human genomic DNA are used as controls. This set, therefore, conforms to a 384-well format. DNA from the RH cell lines (50 ng) was PCR amplified in 10µl reactions containing 4.5 pmole of each primer, 40 µM each dNTP, 10% Rediload (Research Genetics, Inc.,
20 Huntsville, AL) and 1/3 X concentration of Advantage cDNA polymerase mix (Clontech, Inc, Palo Alto, CA). PCR was performed using a Tetrad thermocycler in an oil-free system (MJ Research) with the following "touchdown" PCR profile: 3 min denaturing at 94°C followed by 2 cycles of 30 sec at 94°C, 30 sec at 67°C and 30 sec at 68°C; 2 cycles of 30 sec at 94°C, 30 sec at 65°C, and 30 sec at 68°C; and 31 cycles of 30 sec at 94°C, 30 sec at 67°C.

25 Samples were electrophoresed on a 3% agarose gel (1X TBE) containing 0.5µg/ml Ethidium bromide and imaged using the AlphaImager 950 still video system (Alpha Innotech, San Leandro, CA). The collective set of scores (0 = no amplification; 1 = amplification; 2 = uncertain) for a single marker is called an RH vector. The OPG-X marker was assayed in duplicate to reduce errors, and a consensus was generated from the duplicate vectors.

Chromosomal placement of a human OPG-X gene was accomplished using the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research radiation hybrid mapping website.

The sequence was found to map onto Human chromosome 6 at a LOD score of >17. The exact placement is at 6p11.1, essentially on top of D6S452 and 4.92 centiRay (cR) proximal to D6S459: one cR is the distance between markers at which there is a 1% probability of breakage. Based on the radiation dose used to construct this panel, the distance from D6S459 is calculated to be 0.19cM or approximately 190kb.

Example 3. Northern Analysis of Expression of OPG in Various Human Tissues

Materials and Methods

Probe Production. The probes used in the Northern analysis were produced by PCR amplification of an OPG-X gene fragment cloned into pCR2.1 (Invitrogen). The primers used in the amplification bind to the M13 forward and reverse sequencing primer sites in the vector and contain the SP6 and T3 promoters (Primers used to amplify probes from pCR2.1: M13FSP6: 5'-GGA TCC ATT TAG GTG ACA CTA TAG AAG CCC AGT CAC GAC GTT GTA AAA CGA CGG C-3' (SEQ ID NO:17) and M13RT3: 5'-CGG CCG AAT TAC CCT CAC TAA AGG GAC GGA TAA CAA TTT CAC ACA GGA AAC AGC-3' (SEQ ID NO:18). The forward primer (M13FSP6) contains an SP6 promoter on the 5' end and the M13 forward sequencing primer on the 3' end. While the reverse primer (M13RT3) contains the T3 promoter on the 5' end and the M13 reverse sequencing primer on the 3' end.

The probes were amplified using the following protocol. One nanogram of plasmid was combined with M13FSP6 and M13RT3 (0.2 μ M) in 1X PCR buffer (Advantage cDNA Polymerase Kit, Clontech), 200 μ M each dNTP, and 0.5 μ l of Advantage cDNA polymerase mix (50X; Clontech). The mixture was subjected to denaturation at 94°C for 2 minutes and cycled 5 times at 5 seconds 94°C and 3 minutes 72°C, 5 times at 5 seconds 94°C and 3 minutes 70°C and, finally, 15 times at 5 seconds 94°C and 3 minutes 68°C. Following amplification, the PCR products containing the gene fragment of interest were electrophoresed through a 1% low melt agarose gel and purified using the Qiaex II gel extraction kit (Qiagen).

The RNA probe was transcribed using the Stip-EZ RNA probe synthesis kit (Ambion, Inc.) per the manufacturer's instructions. One hundred nanograms of purified probe was labeled

using 25 μ Ci of 33 P-UTP (3 μ M; Amersham) in a synthesis reaction using SP6 RNA polymerase. The choice of polymerase was dependent on which strand was the non-coding strand for this particular probe. Following RNA transcription, 1 μ l of DNase I is added to the tube and incubated for 15 minutes at 37°C. The unincorporated nucleotides are removed using

5 ProbeQuant G-50 micro columns (Pharmacia Biotech) per the manufacturers instructions. Finally, the probe is quantitated using a Bioscan QC-4000 per the manufacturers instructions (Bioscan).

Hybridization. RNA probes were hybridized to four commercially available Northern Blots at 65°C in a Robbins Scientific Model 400 hybridization incubator. The blots were

10 obtained from Clontech Laboratories, Inc., catalog numbers 7756-1, 7760-1, 7759-1, and 7767-1. Briefly, the blots were inserted into 15 x 300mm glass tubes and prehybridized at 65°C in 10 ml of Zip-Hyb (Ambion, Inc.) for 30 minutes. The RNA probe (1.0 x 10⁶ dpm/ml) was added to 1.0 ml 65°C Zip-Hyb and placed in the glass tube with the prehybridized northern. Hybridization of the probe was allowed to proceed for 2 hours. Following hybridization, the buffer was removed

15 and the blots were washed twice for 15 minutes in the glass bottles at 65°C. The first wash was with prewarmed (65°C) 2x SSC, 0.1%SDS, while the second wash was with prewarmed 0.1X SSC, 0.1% SDS. The blots were removed from the glass tubes, wrapped in Saran Wrap and exposed to phosphor screens overnight (Molecular Dynamics). The phosphor screens were scanned the following day on a Molecular Dynamics Storm 840 at 50 micron resolution.

20 **Example 4: Cloning of mouse OPG-X**

A RACE (Rapid Amplification of cDNA Ends) approach was used to obtain the sequence of the mouse OPG-X gene. Primers (5'-TTC CAT CAG CCC ACG AAT CTT CTC CAC-3' (SEQ ID NO:19); 5'-CTC CAC AAC ATC ATT GCG TCG GTG CTG-3' (SEQ ID NO:20) were designed based on the initially available partial mouse OPG-X sequence (667 bp, with a stop

25 codon) and used in a nested 5'-RACE reaction with Advantage cDNA Polymerase and mouse brain Marathon-Ready cDNA (Clontech), according to the manufacturer's instructions. The reaction parameters were as follows: the initial denaturation step (94 °C for 30 s) was followed by 5 cycles of 94 °C for 5 s and 72 °C for 4 min, then 5 cycles of 94 °C for 5 s and 70 °C for 4 min, and finally 25 cycles of 94 °C for 5 s and 68 °C for 4 min. The RACE products were run on

30 a low melting agarose gel, excised and purified with QIAEX II Gel Extraction Kit (Qiagen). The purified products were ligated overnight in the pCR2.1 vector using the TA Cloning Kit

(Invitrogen), as recommended by the manufacturer. The resulting constructs were transformed in One Shot TOP 10F⁺ Ultracomp *E. coli* cells (Invitrogen) using standard procedures for chemical transformation. The transformed cells were plated on LB/Kanamycin/X-Gal/IPTG plates and incubated overnight at 37 °C. The resulting individual colonies were inoculated in
5 LB/Kanamycin/Ampicillin medium and incubated overnight at 37 °C. One L of the resulting culture was used as a template in a long-distance (LD)-PCR with Advantage cDNA Polymerase and vector primers. The reaction parameters were as follows: the initial denaturation step (96 °C for 5 min) was followed by 26 cycles of 96 °C for 1 min, 57 °C for 1 min and 72 °C for 1 min, then a final extension step of 72 °C for 10 min. The resulting PCR products were sequenced with
10 a BigDye Terminator Cycle Sequencing Kit (PE Applied Biosystems), according to the manufacturer's instructions.

Sequence analysis demonstrated that the initial mouse OPG-X sequence was extended with 888 bp in the 5'-direction. New primers (5'-CAT TCT CTG TCC CTT TCT TCC GCA CAC-3' (SEQ ID NO:21); 5'-GAC TGA TAC ATT CCA GGT GGG CAG ATG-3' (SEQ ID
15 NO:22) were designed based on the newly obtained sequence and the cycle of 5'-RACE, product purification, ligation, transformation, LD-PCR and sequencing was repeated. The sequence was further extended in the 5'-direction, resulting in a total sequence (2393 bp) that contained the information, required for the initiation of transgenic experiments. The complete nucleic acid sequence is shown in FIG. 9A, and its encoded polypeptide is shown in FIG. 9B.

20 **Example 5: Effects of OPG-X in Normal Female Mice (MSCR/Cu1)**

Normal female ICR mice from Harlan Labs were given single daily ip injections of protein or vehicle for 7 days. On the eighth day, animals were anesthetized with Isoflurane and bled for determination of CBC and clinical chemistry alterations. Tissues and organs (see
25 protocol) were removed and weighed and collected into formalin for histopathologic evaluation. Selected tissues were snap frozen in liquid nitrogen and analyzed for RNA.

Live Phase and Necropsy Results

Administration of OPG-X did not adversely affect body weight over the course of the study. Liver weights were decreased in OPG-X-treated mice.

Statistically significant alterations in clinical chemistries consisted of slight elevation of globulin and slight decreases in phosphorus in OPG-X treated mice. OPG-X-treated mice also had significant elevations in hemoglobin and red cell count.

5 Tissues from vehicle treated mice were normal. Mice treated with OPGx had a variety of splenic alterations ranging from mild lymphoid hyperplasia with minimal single cell necrosis of lymphocytes to mildly increased extramedullary hematopoiesis. One animal had marked focal submucosal hemorrhage and inflammation in the anterior colon.

10 The reason for the submucosal hemorrhage in one mouse treated with OPGx is unknown but alterations in blood coagulation would have to be considered as gut hemorrhage is common in animals treated with anticoagulants. The mild lymphoid hyperplasia and single cell splenic necrosis may be a result of the intestinal hemorrhage. Similarly, since this was an inflammatory focus, the marrow granulocytic hyperplasia may simply be a response to the local inflammation. However, animal #2 in this group had mildly increased extramedullary hematopoiesis without any obvious underlying cause. The clinical pathology alterations in the erythrogram could
15 suggest a stimulatory effect of this protein on hematopoiesis.

EQUIVALENTS

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with
20 respect to the scope of the appended claims that follow. In particular, it is contemplated by the inventor that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims

What is claimed is:

1. An isolated polynucleotide comprising a sequence at least 85% homologous to a sequence selected from the group consisting of SEQ ID NOs: 1, 5, 7, and 9, and wherein said polynucleotide does not encode a polypeptide greater than 650 amino acids in length.
2. The polynucleotide of claim 1, wherein said polynucleotide comprises SEQ ID NO:1.
3. The polynucleotide of claim 1, wherein said polynucleotide comprises SEQ ID NO:5.
4. The polynucleotide of claim 1, wherein said polynucleotide comprises SEQ ID NO:7.
5. The polynucleotide of claim 1, wherein said polynucleotide comprises SEQ ID NO:9.
6. The polynucleotide of claim 1, wherein said polynucleotide encodes a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:2, 6, 8, and 10.
7. The polynucleotide of claim 1, wherein said polynucleotide encodes a polypeptide which binds to an osteoprotegerin ligand.
8. The polynucleotide of claim 1, wherein said polynucleotide encodes a polypeptide having the amino acid sequence of SEQ ID NO:2.
9. The polynucleotide of claim 1, wherein said polynucleotide encodes a polypeptide having the amino acid sequence of SEQ ID NO 6.
10. The polynucleotide of claim 1, wherein said polynucleotide encodes a polypeptide having the amino acid sequence of SEQ ID NO 8.

11. The polynucleotide of claim 1, wherein said polynucleotide encodes a polypeptide having the amino acid sequence of SEQ ID NO 10.
12. An isolated polynucleotide comprising a sequence at least 85% homologous to the nucleotide sequence of SEQ ID NO3.
13. The polynucleotide of claim 12, wherein said polynucleotide encodes a polypeptide having the amino acid sequence of SEQ ID NO:4.
14. A vector comprising the nucleic acid sequence of claim 1.
15. A vector comprising the nucleic acid sequence of claim 12.
16. A cell comprising the vector of claim 14.
17. A cell comprising the vector of claim 15.
18. A substantially pure polypeptide comprising an amino acid sequence at least 85% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO:2, 6, 8, and 10, wherein said polypeptide is less than 650 amino acids in length.
19. The polypeptide of claim 18, wherein said polypeptide binds to an osteoprotegerin ligand.
20. The polypeptide of claim 18, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:2.
21. The polypeptide of claim 18, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:6.

22. The polypeptide of claim 18, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:8.
23. The polypeptide of claim 18, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:10.
24. A purified polypeptide comprising an amino acid sequence at least 85% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO:4.
25. The polypeptide of claim 24, wherein said polypeptide binds to an osteoprotegerin ligand.
26. The polypeptide of claim 18, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:4.
27. An antibody that specifically binds to the polypeptide of claim 18.
28. The antibody of claim 27, wherein said antibody is a monoclonal antibody.
29. An antibody that specifically binds to the polypeptide of claim 24.
30. The antibody of claim 25, wherein said antibody is a monoclonal antibody.
31. A pharmaceutical composition comprising the nucleic acid of claim 1.
32. A pharmaceutical composition comprising the nucleic acid of claim 12.
33. A pharmaceutical composition comprising the polypeptide of claim 18.
34. A pharmaceutical composition comprising the polypeptide of claim 24.

35. A method of promoting bone growth, said method comprising administering to a patient in need thereof an effective amount of an osteoprotegerin-like polypeptide, or an osteoprotegerin-like polypeptide agonist.

36. The method of claim 35, wherein said patient suffers from osteoporosis or osteopetrosis, or a condition characterized by loss of bone, breakdown of bone tissue, or excessive resorption of bone tissue.

37. A method of promoting bone growth, said method comprising administering to a patient in need thereof an effective amount of an osteoprotegerin-like nucleic acid.

38. The method of claim 37, wherein said patient suffers from osteoporosis or osteopetrosis, or a condition characterized by loss of bone, breakdown of bone tissue, or excessive resorption of bone tissue.

39. A method of inhibiting osteoclast-mediated bone resorption, said method comprising administering to a subject in need thereof an effective amount of an osteoprotegerin-like polypeptide, or an osteoprotegerin-like polypeptide agonist.

40. The method of claim 39, wherein said patient suffers from osteoporosis or osteopetrosis, or a condition characterized by loss of bone, breakdown of bone tissue, or excessive resorption of bone tissue.

41. A method of inhibiting vascular calcification, said method comprising administering to a subject in need thereof an effective amount of an osteoprotegerin-like polypeptide, or an osteoprotegerin-like polypeptide agonist.

42. A method of inhibiting vascular calcification, said method comprising administering to a subject in need thereof an effective amount of an osteoprotegerin-like nucleic acid.

43. A method of modulating cell death, said method comprising contacting a cell with an osteoprotegerin-like polypeptide in an amount sufficient to modulate apoptosis in said cell.

44. The method of claim 43, wherein said contact induces apoptosis in said cell.

45. A method of modulating cell death, said method comprising contacting a cell with an antibody to an osteoprotegerin-like polypeptide in an amount sufficient to modulate apoptosis in said cell.

46. A method of modulating cell death, said method comprising contacting a cell with an osteoprotegerin-like nucleic acid in an amount sufficient to modulate apoptosis in said cell.

1/10

1
81 GCGNCCGCGNNGNGCAAGGTGCTGAGCGCCCTAGAGCCTCCCTTGCCGCTCCCTCCTCTGCCCCGCGCAGCAGTG
CACATGGGGTGTGGAGGTAGATGGGCTCCCGCGCGGAGCGCGGTGGATGCGGCGTGGGAGAGCAGCCGCCGAT
MetGlySerArgProGlyGlyGlyGlyGlyCysGlyAlaGlyGlnLysGlnProProI
161 TCCAGCTGCCCCGCGCGCCCGCCACCTTGGGAGTCCCGGTTTCAGCCATGGGGACCTCTCCGAGCAGCAGCACC GCC
eProAlaAlaProArgAlaProAlaThrLeuArgValProGlySerAlaMetGlyThrSerProSerSerSerThrAlaL
241 TCGCTCCTGCAGCAGCATCGCCCGCGAGCCACGCCAGATGATCGCGGGCTCCCTTCTCTGCTTGGATTCTTAGC
euAlaSerCysSerSerIleAlaArgArgAlaThrAlaThrMetIleAlaGlySerLeuLeuLeuGlyPheLeuSer
321 ACCACCACAGCTCAGCCAGAACAGAGGCCCTCGAATCTCATTGGCACATACCGCCATGTTGACCGTGCCACCGGCCAGGT
ThrThrThrAlaGlnProGluGlnLysAlaSerAsnLeuIleGlyThrTyrArgHisValAspArgAlaThrGlyGlnVa
401 GCTCAACTGTGACAAGTGTCCAGCAGGAACCTATGTCTCTGAGCATTGTACCAACACAAGCCTGCGCGTGTGCAGCAGTT
lLeuAsnCysAspLysCysProAlaGlyThrTyrValSerGluHisCysThrAsnThrSerLeuArgValCysSerSerC
481 GCCCTGTGGGGACCTTTACCAGGCATGAGAATGGCAGATAGAGAAATGCCATGACTGTAGTCAGCCATGCCCATGGCCAATG
ysProValGlyThrPheThrArgHisGluAsnGlyIleGluLysCysHisAspCysSerGlnProCysProTrpProMet
561 ATTGAGAAATTACCTTGTGCTGCCTTGACTGACCGAGAATGCACTTGCCACCTGGCATGTTCCAGTCTAACGTACCTG
IleGluLysLeuProCysAlaAlaLeuThrAspArgGluCysThrCysProProGlyMetPheGlnSerAsnAlaThrCy
641 TGCCCCCATACGGTGTGCTGTGGGTGGGGTGTGCGGAAGAAAGGGACAGAGACTGAGGATGTGCGGTGTAAGCAGT
sAlaProHisThrValCysProValGlyTrpGlyValArgLysLysGlyThrGluThrGluAspValArgCysLysGlnC
721 GTGCTCGGGGTACCTTCTCAGATGTGCCTTCTAGTGTGATGAAATGCAAAGCATAACAGACTGTCTGAGTCAGAACCTG
ysAlaArgGlyThrPheSerAspValProSerSerValMetLysCysLysAlaTyrThrAspCysLeuSerGlnAsnLeu
801 GTGGTGATCAAGCGGGGACCAAGGAGACAGACAACGTCTGTGGCACACTCCCGTCTTCTCCAGCTCCACCTCACCTTC
ValValIleLysProGlyThrLysGluThrAspAsnValCysGlyThrLeuProSerPheSerSerSerThrSerProSe
881 CCCTGGCACAGCCATCTTCCACGCCCTGAGCACATGGAAACCCATGAAGTCCCTTCTCCACTTATGTTCCCAAAGGTA
rProGlyThrAlaIlePheProArgProGluHisMetGluThrHisGluValProSerSerThrTyrValProLysGlyA
961 ACTTAACCTCATGAATTATTTATTTGAGGAAGGCTTTGAGCCAGTGAGGTACCAAGAGTGGGCTTATACCAAAGATGT
snLeuThrSer
1041 TTTCTCCATTTCTGTATTCCAAAGTCACCCCTTGGAGAGAGGCCTTCATATGGTGGCTAATTAATCTGGCTTTTTTGG
1121 ACTTAATAGAAACATGTAGACTCAGAATTTTCTGTTAGGGGAGATCAGATATCTAAAACTAGGTCACATCAAGCTATA
1201 AAATATGAACCAAGAGAAACAAGGACAGCGTGTGACCTTATGTAAGTTACTTAACCTCTTCAGGCCTCAGTTTCAAACCTT
1281 GTCAAAACAAATGAATAATTTAGATGTTTAAGGTTCTTCCAGATCAAAAGTTTTCACATGAGATCAGTCCCAGGTAGA
1361 CATAGCCAGGAGCAGAGAAGAGGGAGAAAGGAAGAAATACCATTACATCCGGAAGCGAGAGATGAATTTGAATCCAGG
1441 TGGGGCAAAGAATGGGTAGGAAAGTTAGAAGCTCAGGAAATAAGCAAATTTGTATCAGATTGAAGGTAACAGCACTCAT
1521 GTCTGGAATAATAACTTTATTTTTTCAAATGATTTTAACTTTACTCCTTATATCAATTATTCAAGTTTTCCATCAGA
1601 ACCTCAAGCAGAATATAAAATTTATCCTTTATTTTCAAATCCTTTTGTATTAATGTAATTTTCATGAGATGATGACCAA
1681 CTTGAG

Fig. 1

2/10

1 GCGNCCGCGNNGNGNGCAAGGTGCTGAGCGCCCTAGNGCCTCCCTTGCCGCTCCCTCCTCTGCCCGCCGTAGCAGTG
81 CACATGGGGTGTGGAGGTAGATGGGCTCCCGCCGGGAGCGCGGTGGATGCGGCGCTGGGCAGAAGCAGCCGCCGAT
MetGlySerArgProGlyGlyGlyGlyGlyCysGlyAlaGlyGlnLysGlnProProIle
161 TCCAGCTGCCCCGCGCGCCCGGGCACCTTGCGAGTCCCGGTTCCAGCCATGGGGACCTCTCCGAGCAGCAGCAGCCGCC
eProAlaAlaProArgAlaProGlyThrLeuArgValProGlySerAlaMetGlyThrSerProSerSerSerThrAlaL
241 TCGCCTCTGCAGCCGCATCGCCCGCCGAGCCACAGCCAGATGATCGCGGCTCCCTTCTCCTGCTTGGATTCTTACG
euAlaSerCysSerArgIleAlaArgArgAlaThrAlaThrMetIleAlaGlySerLeuLeuLeuLeuGlyPheLeuSer
321 ACCACCAGCTCAGCCAGAACAGAAGGCCCTCGAATCTCATTTGGCACATACCGCCATGTTGACCGTGCCACCGGCCAGGT
ThrThrThrAlaGlnProGluGlnLysAlaSerAsnLeuIleGlyThrTyrArgHisValAspArgAlaThrGlyGlnVa
401 GCTAACCTGTGACAAGTGTCCAGCAGGAACCTATGTCTGTGAGCATTGTACCAACACAAGCCTGCGCGTGTGCAGCAGTT
lLeuThrCysAspLysCysProAlaGlyThrTyrValSerGluHisCysThrAsnThrSerLeuArgValCysSerSerC
481 GCCCTGTGGGACCTTTACCAGGCATGAGAAATGGCATAGAGAAATGCCATGACTGTAGTCAGCCATGCCCATGGCCAAATG
ysProValGlyThrPheThrArgHisGluAsnGlyIleGluLysCysHisAspCysSerGlnProCysProTrpProMet
561 ATTGAGAAATTACCTTGTGCTGCCTTGACTGACCGAGAATGCACCTTGCCACCTGGCATGTTCCAGTCTAACGCTACCTG
IleGluLysLeuProCysAlaAlaLeuThrAspArgGluCysThrCysProProGlyMetPheGlnSerAsnAlaThrCy
641 TGCCCCCATAACGGTGTGTCTGTGGGTGGGGTGTGCGGAAGAAAGGGACAGAGACTGAGGATGTGCGGTGTAAGCAGT
sAlaProHisThrValCysProValGlyTrpGlyValArgLysLysGlyThrGluThrGlnAspValArgCysLysGlnC
721 GTGCTCGGGGTACCTTCTCAGATGTGCCTTCTAGTGTGATGAAATGCAAAGCATAACAGACTGTCTGAGTCAGAACCTG
ysAlaArgGlyThrPheSerAspValProSerSerValMetLysCysLysAlaTyrThrAspCysLeuSerGlnAsnLeu
801 GTGGTGATCAAGCCGGGACCAAGGAGACAGACAACGCTGTGGCACAACCTCCGTCCTTCTCCAGCTCCACCTCACCTTC
ValValIleLysProGlyThrLysGluThrAspAsnValCysGlyThrLeuProSerPheSerSerSerThrSerProSe
881 CCCTGGCAGACCATCTTCCACGCCCTGAGCACATGGAACCCATGAAGTCCCTTCTCCACTTATGTTCCCAAAGGCA
rProGlyThrAlaIlePheProArgProGluHisMetGluThrHisGluValProSerSerThrTyrValProLysGlyM
961 TGAAGTCAACAGAATCCAACCTTCTGCCTCTGTTAGACCAAAGGTACTGAGTAGCATCCAGGAAGGGACAGTCCCTGAC
etAsnSerThrGluSerAsnSerSerAlaSerValArgProLysValLeuSerSerIleGlnGluGlyThrValProAsp
1041 AACACAAGCTCAGCAAGGGGAAGGAAGACGTGAACAAGACCTCCCAAACCTTCAGGTAGTCAACCACCAGCAAGCCCC
AsnThrSerSerAlaArgGlyLysGluAspValAsnLysThrLeuProAsnLeuGlnValValAsnHisGlnGlnGlyPr
1121 CCACCACAGACACATCTGAAGCTGCTGCCGTCCATGGAGGCCACTGGGGGCGAGAAGTCCAGCAGCCCATCAAGGCC
oHisHisArgHisIleLeuLysLeuLeuProSerMetGluAlaThrGlyGlyGluLysSerSerThrProIleLysGlyP
1201 CCAAGAGGGGACATCCTAGACAGAACCTACACAAGCATTGACATCAATGAGCATTGCGCTGGATGATTGTGCTTTTC
roLysArgGlyHisProArgGlnAsnLeuHisLysHisPheAspIleAsnGluHisLeuProTrpMetIleValLeuPhe
1281 CTGCTGCTGGTCTTGTGGTGAATTGTGGTGTGCAGTATCCGAAAAGCTCGAGGACTCTGAAAAGGGGCCCCGGCAGGA
LeuLeuLeuValLeuValIleValValCysSerIleArgLysSerSerArgThrLeuLysLysGlyProArgGlnAs
1361 TCCAGTGCCATTGTGGAAAAGGCAGGGCTGAAGAAATCCATGACTCCAACCCAGAACCGGGAGAAATGGATCTACTACT
pProSerAlaIleValGluLysAlaGlyLeuLysSerMetThrProThrGlnAsnArgGluLysTrpIleTyrTyrC
1441 GCAATGGCCATGGTATCGATATCCTGAAGCTTGTAGCAGCCCAAGTGGGAAGCCAGTGGAAAGATATCTATCAGTTTCTT
ysAsnGlyHisGlyIleAspIleLeuLysLeuValAlaAlaGlnValGlySerGlnTrpLysAspIleTyrGlnPheLeu
1521 TGCAATGCCAGTGAGAGGGAGGTTGCTGCTTTCTCCAATGGGTACACAGCCGACCAGCGGGCCTACGCAGCTCTGCA
CysAsnAlaSerGluArgGluValAlaAlaPheSerAsnGlyTyrThrAlaAspHisGluArgAlaTyrAlaAlaLeuG1
1601 GCACTGGACCATCCGGGGCCCCGAGGCCAGCTCGCCAGCTAATTAGCGCCCTGCGCCAGCACCAGGAGAAACGATGTTG
nHisTrpThrIleArgGlyProGluAlaSerLeuAlaGlnLeuIleSerAlaLeuArgGlnHisArgArgAsnAspValV
1681 TGGAGAAGATTCTGGGCTGATGGAAGACACCCAGCTGGAAACTGACAACTAGCTCTCCCGATGAGCCCCAGCCCC
AlGluLysIleArgGlyLeuMetGluAspThrThrGlnLeuGluThrAspLysLeuAlaLeuProMetSerProSerPro

Fig. 2

3/10

1761 CTTAGCCCGAGCCCCATCCCCAGCCCCAACGCGAAACTTGAGAATTCGGCTCTCCTGACGGTGGAGCCTTCCCCACAGGA
LeuSerProSerProIleProSerProAsnAlaLysLeuGluAsnSerAlaLeuLeuThrValGluProSerProGlnAs
1841 CAAGAACAAGGGCTTCTTCGTGGATGAGTCGGAGCCCCCTTCTCCGCTGTGACTCTACATCCAGCGGCTCCTCCGCGCTGA
pLysAsnLysGlyPhePheValAspGluSerGluProLeuLeuArgCysAspSerThrSerSerGlySerSerAlaLeuS
1921 GCAGGAACGGTTCCTTTATTACCAAAGAAAAGAAGGACACAGTGTTCGGGCAGGTACGCCTGGACCCCTGTGACTTGCCAG
erArgAsnGlySerPheIleThrLysGluLysLysAspThrValLeuArgGlnValArgLeuAspProCysAspLeuGln
2001 CCTATCTTTGATGACATGCTCCACTTTCTAAATCCTGAGGAGCTGCGGGTGATTGAAGAGATTCCCCAGGCTGAGGACAA
ProIlePheAspAspMetLeuHisPheLeuAsnProGluGluLeuArgValIleGluGluIleProGlnAlaGluAspLy
2081 ACTAGACCGGCTATTCGAAATTATTGGAGTCAAGAGCCAGGAAGCCAGCCAGACCCTCCTGGACTCTGTTTATAGCCATC
sLeuAspArgLeuPheGluIleIleGlyValLysSerGlnGluAlaSerGlnThrLeuLeuAspSerValTyrSerHisL
2161 TTCCTGACCTGCTGTAGAACATTAGGGATACTGCATTCTGGAATTACTCAATTTAGTGGCAGGGTGGTTTTTTANTTTT
euProAspLeuLeu
2241 CTTCTGTTTCTGATTTTTGTTGTTTGGGGTG

Fig. 2 (CONT'D)

4/10

OSTEOPROTEGERIN - HOMO SAPIENS (HUMAN), 401 aa.

Length = 401

Score = 285 (100.3 bits), Expect = 4.1e-25, P = 4.1e-25
 Identities = 56/158 (35%), Positives = 77/158 (48%)

```

Query:   54 YRHVD RATGQVLNCDKCPAGTYVSEHCTNTSLRVCSSCPVGTFTRHENGIEKCHDCSQPC 113
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sbjct:   28 YLHYDEETSHQLLCDKCPPGTYLKQECTAKWKTVCAPCPDHYTDSWHTSDECLYCSFVC 87

Query:  114 PWPMEIKLPAAALTDRECTCPPGMFQSNATCAPHTVCPVWGVRKKGTTEDVRCKQCAR 173
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sbjct:   88 KELQYVKQECNRTHNRVCECKEGRYLEIEFCLKHRSCPPGFGVVQAGTPERNTVCKRCPD 147

Query:  174 GTFSDVPSSVMKCKAYTDCLSQNLVVIKPGTKETDNVC 211
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sbjct:  148 GFFSNETSSKAPCRKHTNCSVFGLLLTQKGNATHDNIC 185
  
```

Fig. 3

TUMOR NECROSIS FACTOR RECEPTOR - HOMO SAPIENS (HUMAN), 425 aa.

Length = 425

Score = 293 (103.1 bits), Expect = 5.8e-26, P = 5.8e-26
 Identities = 72/189 (38%), Positives = 91/189 (48%)

```

Query:   61 TGQVLNCDKCPAGTYVSEHCTNTSLRVCSSCPVGTFTRHENGIEKCHDCSQPCPWPMEIK 120
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sbjct:   13 TAQMC-CSKCSPGQHAQVCTKTSDTVCDSCEDSTYQLWNWVPECLSCGSRCSDDQVET 71

Query:  121 LPAAALTDRECTCPPGMF-----QSNAT-CAPHTVCPVWGVRKKGTTEDVRCKQCARG 174
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sbjct:   72 QACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPG 131

Query:  175 TFSVPSSVMKCKAYTDCLSQNLVVIKPGTKETDNVCGTLPSSSTSPSPGTAIFPRP- 233
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sbjct:  132 TFSNTTSSDTCRPHQIC---NVVAI-PGNASMDAVC---TSTSPTRSMAPGAVHLPQPV 184

Query:  234 --EHMETHEVPSSTYVP 248
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sbjct:  185 STRSQHTQPTPEPSTAP 201
  
```

Fig. 4

5/10

1 CCGGTTTCAGCCATGGGGACCTCTCCGAGCAGCAGCACCGCCCTCG
MetGlyThrSerProSerSerSerThrAlaLeuA
46 CCTCCTGCAGCCGCATCGCCCGCCGAGCCACAGCCACGATGATCG
laSerCysSerArgIleAlaArgArgAlaThrAlaThrMetIleA
91 CGGGCTCCCTTCTCCTGCTTGGATTTCCTTAGCACCACCACAGCTC
laGlySerLeuLeuLeuLeuGlyPheLeuSerThrThrThrAlaG
136 AGCCAGAACAGAAGGCCTCGAATCTCATTGGCACATACCGCCATG
lnProGluGlnLysAlaSerAsnLeuIleGlyThrTyrArgHisV
181 TTGACCGTGCCACCGGCCAGGTGCTAACCTGTGACAAGTGTCAG
alAspArgAlaThrGlyGlnValLeuThrCysAspLysCysProA
226 CAGGAACCTATGTCTCTGAGCATTGTACCAACACAAGCCTGCGCG
laGlyThrTyrValSerGluHisCysThrAsnThrSerLeuArgV
271 TCTGCAGCAGTTGCCCTGTGGGGACCTTTACCAGGCATGAGAATG
alCysSerSerCysProValGlyThrPheThrArgHisGluAsnG
316 GCATAGAGAAAATGCCATGACTGTAGTCAGCCATGCCCATGGCCAA
lyIleGluLysCysHisAspCysSerGlnProCysProTrpProm
361 TGATTGAGAAATTACCTTGTGCTGCCTTGACTGACCGAGAATGCA
etIleGluLysLeuProCysAlaAlaLeuThrAspArgGluCysT
406 CTTGCCCACCTGGCATGTTCCAGTCTAACGCTACCTGTGCCCCC
hrCysProProGlyMetPheGlnSerAsnAlaThrCysAlaProH
451 ATACGGTGTGTCCTGTGGGTGGGGTGTGCGGAAGAAAGGGACAG
isThrValCysProValGlyTrpGlyValArgLysLysGlyThrG
496 AGACTGAGGATGTGCGGTGTAAGCAGTGTGCTCGGGGTACCTTCT
luThrGluAspValArgCysLysGlnCysAlaArgGlyThrPheS
541 CAGATGTGCCTTCTAGTGTGATGAAATGCAAAGCATACACAGACT
erAspValProSerSerValMetLysCysLysAlaTyrThrAspC
586 GTCTGAGTCAGAACCTGGTGGTGATCAAGCCGGGGACCAAGGAGA
ysLeuSerGlnAsnLeuValValIleLysProGlyThrLysGluT
631 CAGACAACGTCTGTGGCACACTCCCGTCTTCTCCAGCTCCACCT
hrAspAsnValCysGlyThrLeuProSerPheSerSerSerThrS
676 CACCTTCCCCTGGCACAGCCATCTTCCACGCCCTGAGCACATGG
erProSerProGlyThrAlaIlePheProArgProGluHisMetG
721 AAACCCATGAAGTCCCTTCTCCACTTATGTTCCCAAAGGTAAC
luThrHisGluValProSerSerThrTyrValProLysGlyAsnL
766 TAACCTCA
euThrSer

Fig. 5

6/10

1 GCGNCCGCGNNGNGNGCAAGGTGCTGAGCGCCCTAGAGCCTCCC
46 TTGCCGCTCCCTCCTCTGCCCGGCCGTAGCAGTGACATGGGGT
91 GTTGGAGGTAGATGGGCTCCCGCCGGGAGGCGCGGTGGATGCG
MetGlySerArgProGlyGlyGlyGlyGlyCysG
136 GCGCTGGGCAGAAGCAGCCGCCGATTCCAGCTGCCCCGCGCGCC
lyAlaGlyGlnLysGlnProProIleProAlaAlaProArgAlaP
181 CGGCCCCCTTGCAGTCCCCGGTTCAGCCATGGGGACCTCTCCGA
roAlaProLeuArgValProGlySerAlaMetGlyThrSerProS
226 GCAGCAGCACCTCCCTCGCCTCCTGCAGCCGCATCGCCGCGGAG
erSerSerThrSerLeuAlaSerCysSerArgIleAlaArgArgA
271 CCACAGCCACTATGATCGCGGGCTCCCTTCTCCTGCTTGGATTCC
laThrAlaThrMetIleAlaGlySerLeuLeuLeuLeuGlyPheL
316 TTAGCACCACCACAGCTCAGCCAGAACAGAAGGCCTCGAATCTCA
euSerThrThrThrAlaGlnProGluGlnLysAlaSerAsnLeuI
361 TTGGCACATACCGCCATGTTGACCGTGCCACCGCCAGGTGCTTA
leGlyThrTyrArgHisValAspArgAlaThrGlyGlnValLeuA
406 ACTGTGACAAGTGTCCAGCAGGAACCTATGTCTCTGAGCATTGTA
snCysAspLysCysProAlaGlyThrTyrValSerGluHisCysT
451 CCAACACAAGCCTGCGCGTCTGCAGCAGTTGCCCTGTGGGGACCT
hrAsnThrSerLeuArgValCysSerSerCysProValGlyThrP
496 TTACCAGGCATGAGAATGGCATAGAGAAATGCCATGACTGTAGTC
heThrArgHisGluAsnGlyIleGluLysCysHisAspCysSerG
541 AGCCATGCCCATGGCCAATGATTGAGAAATTACCTTGTGCTGCCT
lnProCysProTrpProMetIleGluLysLeuProCysAlaAlaL
586 TGACTGACCGAGAATGCACTTGCCACCTGGCATGTTCCAGTCTA
euThrAspArgGluCysThrCysProProGlyMetPheGlnSerA
631 ACGCTACCTGTGCCCCCATACGGTGTGTCTGTGGGTGGGGTG
snAlaThrCysAlaProHisThrValCysProValGlyTrpGlyV
676 TGCGGAAGAAAGGGACAGAGACTGAGGATGTGCGGTGTAAGCAGT
alArgLysLysGlyThrGluThrGluAspValArgCysLysGlnC
721 GTGCTCGGGGTACCTTCTCAGATGTGCCTTCTAGTGTGATGAAAT
ysAlaArgGlyThrPheSerAspValProSerSerValMetLysC
766 GCAAAGCATAACAGACTGTCTGAGTCAGAACCTGGTGGTGATCA
ysLysAlaTyrThrAspCysLeuSerGlnAsnLeuValValIleL
811 AGCCGGGGACCAAGGAGACAGACAACGTCTGTGGCACACTCCCGT
ysProGlyThrLysGluThrAspAsnValCysGlyThrLeuProS
856 CCTTCTCCAGCTCCACCTCACCTTCCCCTGGCACAGCCATCTTTC
erPheSerSerSerThrSerProSerProGlyThrAlaIlePheP
901 CACGCCCTGAGCACATGGAAACCCATGAAGTCCCTTCCTCCACTT
roArgProGluHisMetGluThrHisGluValProSerSerThrT
946 ATGTTCCCAAAGGTAACCTAACCTCATGAATTATTTATTTGAGGA
YrValProLysGlyAsnLeuThrSer

Fig. 6

7/10

991 AGGCTTTGAGCCCAGTGGAGGTACCAAGAGTGGGCTTATACCAA
1036 GATGTTTTCTCCATTTCTGTATTCCAAAGTCACCCCTTGGAGAG
1081 AGGCCTTCATATGGTGGCTAATTAAATCTGGCTTTTTTGGACTTA
1126 ATAGAAACATGTAGACTCAGAATTTTCTGTAGGGGAGATCAGA
1171 TATCTAAAAANTAGGTCACATCAAGCTATAAAATATGAACCAAGA
1216 GAANCAAGGACAGCGTGTGACCTTATGTAAGTTACTTAACCTCTT
1261 CAGGCCTCAGTTTCAAACCTTGTCAAACAAATGAATAATTTAGATG
1306 TTTAAGGTTCCCTCCAGATCAAAAGTTTTCCAACATGGAGTCAGT
1351 CCCAGGTAGACATAGCCAGGAGCAGAGAAGAGGGAGAAAGGAAGA
1396 AAATACCATTACATCCGGAAGCGAGAGATGAATTTTGAATCCAGG
1441 TGGGGCAAAGAATGGGTAGGAAAGTTAGAAGCTCAGGAAATAAGC
1486 AAATTTGTATCAGATTGAAGGTAAGTACTAGCACTCATGTCTGAAAA
1531 TAATAACTTTATTTTTTCCAAATGATTTTAACTTTACTCCTTATA
1576 TCAATTATTCAAGTTTTCCATCAGAACCTCAAGCAGAAATATAAAA
1621 TTTATCCTTTATTTTCAAATCCTTTTTTGATTTAATGTAATTTTCA
1666 TGAGATGATGACCAACTTGAG

Fig. 6 (CONT'D)

8/10




Fig. 7A




Fig. 7B




Fig. 8

9/10

A. DNA sequence of murine OPGx:

1 GGCCATGGGGACCCGGGCAAGCAGCATCACCGCCCTCGCCTCTTGAGCCGCACCGCCGGCCAAGTCGGAGCCACGATGG
81 TCGCCGGCTCTCTTCTCCTGCTTGGATTCTCTCAGCACCATCACAGCTCAACCAGAACAAAAGACTCTGAGTCTCCCTGGC
161 ACCTACCGCCATGTTGACCGTACCCTGGCCAGGTGCTAACCTGCGACAAGTGCCAGCAGGAACGTATGTCTCCGAGCA
241 CTGTACCAACATGAGCCTGCGAGTCTGCAGCAGCTGCCCCGCGGGGACCTTTACCAGGCACGAGAACGGCATAGAGAGAT
321 GCCATGACTGTAGTCAGCCATGTCCATGGCCGATGATTGAGAGATTACCTTGTGCTGCCTTGACTGACCGAGAGTGCATC
401 TGCCACCTTGGAAATGTATCAGTCTAATGGTACCTGCGCTCCCCATACAGTGTGCCCCGTGGGCTGGGGTGTGCGGAAGAA
481 AGGGACAGAGAATGAAGATGTGCGCTGTAAGCAGTGCCTCGGGGTACCTTCTCTGACGTGCCTTCCAGTGTGATGAAGT
561 GTAAAGCTCACACGGACTGTCTGGGTGAGAACCTGGAGGTGGTCAAGCCAGGGACCAAGGAGACAGACAACGTCTGTGGC
641 ATGCGCCTGTTCTTCTCCAGCACAAACCCACCTTCTCTGGCACAGTTACCTTTTCTCACCCTGAGCATATGGAATCCCA
721 CGATGTCCCTTCTCCACCTATGAGCCCCAAGGCATGAACTCAACAGATTCCAACCTCTACTGCCTCTGTTAGAACTAAGG
801 TACCAAGTGGCATCGAGGAAGGGACAGTGCCTGACAATACGAGCCCAACCAGTGGGAAGGAAGGCACTAATAGGACCTG
881 CCAAACCCACCACAAGTTACCCACCAGCAAGCCCCCACCACAGACACATTCTGAAGCTGCTGCCATCGTCCATGAAGGC
961 CACGGGTGAGAAGTCCAGCACGCCATCAAGGCCCCAAGAGGGGTCACCCCAGACAGAACGCTCACAAGCATTTTCGACA
1041 TCAACGAGCACTTGCCTTGGATGATCGTCTCTTCTCTGCTGGTCTGCTGATAGTGGTGTGCAGTATCCGAAAG
1121 AGCTCCAGGACTCTCAAAAAGGGGCCCCGGCAGGATCCAGCGCCATAGTGGAAAAGGCGGGGCTGAAGAAGTCCCTGAC
1201 TCCCACCCAGAACCGGGAGAAATGGATCTACTACCGCAACGGCCATGGTATTGACATCTTGAAGCTTGTAGCAGCCCAGG
1281 TGGGAAGCCAGTGGGAAGGACATCTATCAGTTTCTTTGCAACGCCAGCGAGAGGGAGGTGGCGGCCCTTCTCCAATGGATAC
1361 ACTGCAGATCAGAACGGGCTACGCGGCTCTGCAGCACTGGACCATCCGTGGCCCTGAGGCCAGCCTTGCCCAGCTCAT
1441 TAGCGCCTTGCAGCAGCACCGCAATGATGTTGTGGAGAAGATTGCTGGGCTGATGGAAGACACCACAGTTGGAAA
1521 CAGACAAACTGGCTCTCCCCATGAGCCCCAGTCCGCTGAGCCCCGAGCCCCATCCCCAGTCTAACGTGAAACTTGAGAA
1601 TCCACTCTCTGACAGTGGAGCCCTCACCGCTGGACAAGAACAAGTGCTTCTTCGTGGACGAAGTCAGAGCCCCCTTCTGC
1681 GTTGCAGACTCCACATCCAGTGGCTCTTCAGCACTGAGCAGAAACGGCTCCTTTATTACCAAAGGTACCCATCTCTTGTGA
1761 AGCCTGGGGCCATCTTCTTGACACTCCACAGCGAGTTGTAGCTGAGCCCACTTGAATGACCTGTTAGGAGACCTCCAA
1841 GATGAAAGTGTCTCAAGGAAGCCACATCACTAATTAACATGGATACNCCTAGAAAAGTCTTTACAACCTGTGCCCTATCC
1921 AGAACCAGCTTTGATACAGGCCCATTAGCGTCTATCCTTGGCATACTATCCAATGTGTGCTTCAGGAGACATCTGACAAA
2001 AGACAGTGTAGCTGATCTGGAGAATTATTTCCACACTTGCTGAGTCTAAGGCTGAAGAGTGAAACCCATCTGGAGAGTC
2081 AGAAGTAGTTTATGTTTGAATTTGATCCTAAAATTCACCTCTAAACTAGATTGCACACATTTTCAGCATAGTAGGGGAG
2161 GGGGCTAGGGCTCAGTTGGTAAGGTGCCTAGCAGGCATGAAGCCCAGCAGACACAAAAACAGAGTGTGGTGGCTCT
2241 CAGTTGGTATTTTAGCATTGAGAAAATATGCAATTCAAAGTCAGCTGGGTGTGGTGGGAGACTCCTTTGATCCCAGCAC
2321 TTAAGAAAGAGAGCTAGAATTACGCGGCCGCTTTTCTTACCTGCCCCGGCGGCCGCTCGAGCCCTATAGTGAG

Fig. 9

10/10

B. Protein sequence of murine OPGx:

1 MGTRASSITALASCRTAGQVGATMVAGSLLLLGFLSTITAQPEQKTLSPGTYRHVDRTTGQVLTCDKCPAGTYVSEHC
81 TNMSLRVCSSCPAGTFTRHENGIERCHDCSQPCPWPMIERLPCAALTDRECICPPGMYQSNGTCAPTHVCPVGGVVRKKG
161 TENEDVRCKQCARGTFSDVPSSVMKCKAHTDCLGQNLEVVKPGTKETDNVCGMRLFFSSTNPPSSGTVTFSHPEHMESH
241 VPSSTYEPQGMNSTDSNSTASVRTKVPSGIEEGTVPDNTSPTSGKEGTNRTLPPNPQVTHQQAPHHRHILKLLPSSMKAT
321 GEKSSTAIAKAPKRGHPRQNAHKHFDINEHLPWMIVLFLLLVLVLIVVCSIRKSSRTLKKGPRQDPSAIVEKAGLKSLTP
401 TQNRKWIYYRNGHGIDILKLVAQVGSQWKDIYQFLCNASEREVAASFNGYTADHERAYAAHQHTIRGPEASLAQLIS
481 ALRQHRRNDVVEKIRGLMEDTTQLETDKLALPMSPSPSPSPNPKLENSTLLTVEPSPLDKNKCFVDEVRAPSAL
561 RLHIQWLFSTEQKRLLYYQRYPSLVKPGAIFLDTQPQRSCS

Fig. 9 (CONT'D)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C12N15/12, C07K 14/705, 16/18, 14/715, A61K 48/00, 38/17</p>	<p>A3</p>	<p>(11) International Publication Number: WO 00/24771</p> <p>(43) International Publication Date: 4 May 2000 (04.05.00)</p>																										
<p>(21) International Application Number: PCT/US99/24913</p> <p>(22) International Filing Date: 22 October 1999 (22.10.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%;"> <tr> <td style="width: 60%;">60/105,481</td> <td style="width: 20%;">23 October 1998 (23.10.98)</td> <td style="width: 20%;">US</td> </tr> <tr> <td>60/156,993</td> <td>1 October 1999 (01.10.99)</td> <td>US</td> </tr> <tr> <td>09/422,680</td> <td>21 October 1999 (21.10.99)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table style="width: 100%;"> <tr> <td style="width: 60%;">US</td> <td style="width: 20%;">60/105,481 (CIP)</td> <td style="width: 20%;"></td> </tr> <tr> <td>Filed on</td> <td>23 October 1998 (23.10.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/156,993 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>1 October 1999 (01.10.99)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>21 October 1999 (21.10.99)</td> <td></td> </tr> </table> <p>(71) Applicant (for all designated States except US): CURAGEN CORPORATION [US/US]; 11th floor, 555 Long Wharf Drive, New Haven, CT 06511 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US).</p>	60/105,481	23 October 1998 (23.10.98)	US	60/156,993	1 October 1999 (01.10.99)	US	09/422,680	21 October 1999 (21.10.99)	US	US	60/105,481 (CIP)		Filed on	23 October 1998 (23.10.98)		US	60/156,993 (CIP)		Filed on	1 October 1999 (01.10.99)		US	Not furnished (CIP)		Filed on	21 October 1999 (21.10.99)		<p>YANG, Meijia [CN/US]; 6 Catbird Lane, East Lyme, CT 06533 (US). LICHENSTEIN, Henri [US/US]; 24 Sheep Pasture Road, Madison, CT 06443 (US). MCDONALD, William, F. [US/US]; 343 Warpas Road, Madison, CT 06443 (US).</p> <p>(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p> <p>(88) Date of publication of the international search report: 9 November 2000 (09.11.00)</p>
60/105,481	23 October 1998 (23.10.98)	US																										
60/156,993	1 October 1999 (01.10.99)	US																										
09/422,680	21 October 1999 (21.10.99)	US																										
US	60/105,481 (CIP)																											
Filed on	23 October 1998 (23.10.98)																											
US	60/156,993 (CIP)																											
Filed on	1 October 1999 (01.10.99)																											
US	Not furnished (CIP)																											
Filed on	21 October 1999 (21.10.99)																											
<p>(54) Title: NUCLEIC ACIDS ENCODING OSTEOPROTEGERIN-LIKE PROTEINS AND METHODS OF USING SAME</p>																												
<p>(57) Abstract</p> <p>Disclosed are osteoprotegerin-like polypeptides, nucleic acids encoding osteoprotegerin-like polypeptides, and methods of using these molecules. The osteoprotegerin-like polypeptides sequence homology to osteoprotegerin and tumor necrosis factor receptor molecules.</p>																												

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/24913

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/12 C07K14/705 C07K16/18 C07K14/715 A61K48/00 A61K38/17		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EP 0 869 179 A (SMITHKLINE BEECHAM CORP) 7 October 1998 (1998-10-07)</p> <p>SEQ ID No:1: 99% id. in 767 bp of SEQ ID No:1, 99.9% id. in 2068 bp of SEQ ID No:3, 99.3% id. in 767 bp of SEQ ID No:5, 98.8% id. in 767 bp of SEQ ID No:7 and 86.8% id. in 1745 bp of SEQ ID No:9 page 11 -page 22</p> <p style="text-align: center;">--- -/--</p>	<p>1,6-19, 24,25, 27,29, 31-46</p>
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
<p>* Special categories of cited documents :</p> <div style="display: flex;"> <div style="flex: 1;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*&* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">1 August 2000</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">24.08.00</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Nichogiannopoulou, A</div>

International Application No
PCT/US 99/24913

4

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/24913

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SIMONET W S ET AL: "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density" CELL, vol. 89, 18 April 1997 (1997-04-18), pages 309-319, XP002090117 ISSN: 0092-8674	1-46
A	SMITH C A ET AL: "THE TNF RECEPTOR SUPERFAMILY OF CELLULAR AND VIRAL PROTEINS: ACTIVATION, COSTIMULATION, AND DEATH" CELL, vol. 76, 25 March 1994 (1994-03-25), pages 959-962, XP002029050 ISSN: 0092-8674	1-46

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/24913

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 35-46 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 2, 8, 20 all completely and 1, 6, 7, 14, 16, 18, 19, 27, 28, 31, 33, 35-46 all partially

Polynucleotides, polypeptides, vectors, host cells, antibodies, pharmaceutical compositions and methods of treatment relating to human osteoprotegerin-like protein 1 (hu OPGx1, SEQ ID Nos:1 and 2).

2. Claims: 12, 13, 15, 17, 24-26, 29, 30, 32, 34 all completely and 35-46 all partially

As in subject 1, relating to human osteoprotegerin-like protein 2 (hu OPGx2, SEQ ID Nos:3 and 4).

3. Claims: 3, 9, 21 all completely and 1, 6, 7, 14, 16, 18, 19, 27, 28, 31, 33, 35-46 all partially

As in subject 1, relating to human osteoprotegerin-like protein 3 (hu OPGx3, SEQ ID Nos:5 and 6).

4. Claims: 4, 10, 22 all completely and 1, 6, 7, 14, 16, 18, 19, 27, 28, 31, 33, 35-46 all partially

As in subject 1, relating to human osteoprotegerin-like protein 4 (hu OPGx4, SEQ ID Nos:7 and 8).

5. Claims: 5, 11, 23 all completely and 1, 6, 7, 14, 16, 18, 19, 27, 28, 31, 33, 35-46 all partially

As in subject 1, relating to mouse osteoprotegerin-like protein 5 (mu OPGx5, SEQ ID Nos:9 and 10).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/24913

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0869179 A	07-10-1998	US 6013476 A JP 11018786 A	11-01-2000 26-01-1999
EP 0861850 A	02-09-1998	US 5885800 A CA 2220852 A JP 10215886 A	23-03-1999 03-08-1998 18-08-1998
WO 9830694 A	16-07-1998	AU 5815798 A AU 6238698 A CN 1247567 T EP 1007659 A EP 0990031 A WO 9830693 A	03-08-1998 03-08-1998 15-03-2000 14-06-2000 05-04-2000 16-07-1998